皮膚科臨床アセット　8　変貌するざ瘡マネージメント

出版社： 中山書店
著者：
発行日： 2012-01-31
分野： 臨床医学：内科  >  皮膚科
ISBN： 9784521733456
シリーズ： 皮膚科臨床アセット
電子書籍版： 2012-01-31 （初版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

14,850 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

14,850 円(税込)

購入する

商品紹介

患者の増加や治療・対処法の進展により，皮膚科医のざ瘡（ニキビ）に対する知識の必要性が急速に高まった。またざ瘡重症度判定基準や治療ガイドラインも策定された。このような背景のもと，本書ではざ瘡のメカニズムを詳述し，診断のポイントや原因別のざ瘡の鑑別診断を豊富な画像を用い解説。ガイドラインで取り上げられている治療のみならず最新の治療についても取り上げた。皮膚科医・美容外科医，必携の一冊。

目次

  • 皮膚科臨床アセット　8　変貌するざ瘡マネージメント

    ―目次―

    1．頻度・性差
    2．診断基準・鑑別診断
    3．病因論・病態・病理
    4．検査
    5．治療
    6．臨床経過・予後
    7．最新研究からのインサイト

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

I 頻度・性差

P.2 掲載の参考文献
1) 増子倫樹. 女性における脂腺の年齢による形態変化-画像解析と電顕による研究. 日皮会誌 1988 ; 98 : 443-52.
 
2) 池田和人. 男性における脂腺の年齢による形態変化. 日皮会誌 1991 ; 101 : 421-6.
 
3) Burton JL, Cunliffe WJ, Stafford I, et al. The prevalence of acne vulgaris in adolescence. Br J Dermatol 1971 ; 85 : 119-26.
PubMed
4) Walton S, Wyatt E, Cunliffe WJ. Genetic control of sebum excretion and acne. Br J Dermatol 1988 ; 18 : 393-6.
 
5) 林伸和, 川島眞, 渡辺晋一, ほか. 本邦における尋常性ざ瘡のアンケートによる疫学的調査成績. 日皮会誌 2001 ; 111 : 1347-55.
 
6) Hamilton JB, Terada H, Mesteler CE. Greater tendency to acne in white American than Japanese populations. J Clin Endocrinol Metab 1964 ; 24 : 267-72.
 
7) Pillsbury DM, Shelly WB, Kligman AM. Acne and miliaria. In : Dermatology. Philadelphia : Saunders ; 1960. pp273-89.
 
8) O'Brien SC, Lewis JB, Cunliffe WJ, et al. The Leeds revised acne grading system. J Dermatolog Treat 1998 ; 9 : 215-20.
 
9) Hayashi N, Akamatsu H, Kawashima M ; Acne Study Group. Establishment of grading criteria for acne severity. J Dermatol 2008 ; 35 : 255-60.
 
10) 川島眞, 赤松浩彦, 林伸和, ほか. 皮膚科専門医療機関におけるざ瘡患者実態調査. 臨皮 2008 ; 62 : 673-82.
 
11) 黒川一郎, 西嶋攝子. 他のざ瘡性疾患. 玉置邦彦, ほか編. 最新皮膚科学大系 17. 付属器・口腔粘膜の疾患. 東京 : 中山書店 ; 2003. pp131-7.
 
12) 大滝倫子. ニキビダニ症. 玉置邦彦, ほか編. 最新皮膚科学大系 16. 動物性皮膚症環境因子による皮膚障害. 東京 : 中山書店 ; 2003. pp67-9.
 
P.8 掲載の参考文献
1) 林伸和, 川島眞, 渡辺晋一, ほか. 本邦における尋常性ざ瘡のアンケートによる疫学的調査成績. 日皮会誌 2001 ; 111 : 1347-55.
 
2) 倉繁田鶴子, 五十嵐俊弥, 内田勉, ほか. 皮膚科による学校保健に対する取り組みと今後の課題-前橋市. 皮膚病診療 2009 ; 31 : 61-6.
 
3) Rademaker M, Garioch JJ, Simpson NB. Acne in schoolchildren : no longer a concern for dermatologists. Br Med J 1989 ; 298 : 1217-20.
 
4) 川島眞, 赤松浩彦, 林伸和, ほか. 皮膚科専門医療機関におけるざ瘡患者実態調査. 臨皮 2008 ; 62 : 673-82.
 
5) 渡辺靖, 永島敬士, 本田光芳, ほか. 界面活性剤を配合した低刺激性石鹸の尋常性ざ瘡, 脂漏に及ぼす影響. 臨床医薬 1985 ; 1 : 337-45.
 
6) 谷岡未樹, 相場節也, 菊地克子, ほか. 尋常性ざ瘡患者を対象としたざ瘡用化粧品 (医薬部外品) の使用試験. 皮膚の科学 2008 ; 7 : 354-63.
 
7) Matsuoka Y, Yoneda K, Sadahira C, et al. Effects of skin care and makeup under instruction from dermatologists on the quality of life of female patients with acne vulgaris. J Dermatol 2006 ; 33 : 745-52.
PubMed
8) 小林文子, 緒方千秋, 金成俊. 漢方薬服用患者における健康食品の使用実態. 漢方の臨床 2008 ; 55 : 1019-27.
 
9) Bowe WP, Joshi SS, Shalita AR. Diet and acne. J Am Acad Dermatol 2010 ; 63 : 124-41.
PubMed
10) Mueller EA, Trapp S, Frentzel A, et al. Efficacy and tolerability of oral lactoferrin supplementation in mild to moderate acne vulgaris : an exploratory study. Curr Med Res Opin 2011 ; 27 : 793-7.
PubMed
11) Bowe WP, Shalita AR. Effective over-the-counter acne treatments. Semin Cutan Med Surg 2008 ; 27 : 170-6.
PubMed
12) Rubin MG, Kim K, Logan AC. Acne vulgaris, mental health and omega-3 fatty acids : a report of cases. Lipids Health Dis 2008 ; 7 : 36.
PubMed
13) El-Akawi Z, Abdel-Latif N, Abdul-Razzak K. Does the plasma level of vitamins A and E affect acne condition? Clin Exp Dermatol 2006 ; 31 : 430-4.
 
14) Michaelsson G, Edqvist LE. Erythrocyte glutathione peroxidase activity in acne vulgaris and the effect of selenium and vitamin E treatment. Acta Derm Venereol 1984 ; 64 : 9-14.
PubMed
15) Kligman AM, Mills OH Jr, Leyden JJ, et al. Oral vitamin A in acne vulgaris. Preliminary report. Int J Dermatol 1981 ; 20 : 278-85.
PubMed
16) Hayashi N, Higaki Y, Kawamoto K, et al. A cross-sectional analysis of quality of life in Japanese acne patients using the Japanese version of Skindex-16. J Dermatol 2004 ; 31 : 971-6.
PubMed
P.12 掲載の参考文献
1) Ganceviciene R, Graziene V, Fimmel S, et al. Involvement of the corticotropin-releasing hormone system in the pathogenesis of acne vulgaris. Br J Dermatol 2009 ; 160 : 345-52.
PubMed
1) Burton JL, Cunliffe WJ, Stafford I, et al. The prevalence of acne vulgaris in adolescence. Br J Dermatol 1971 ; 85 : 119-26.
PubMed
2) Rasmussen JE, Smith SB. Patient concepts and misconceptions about acne. Arch Dermatol 1983 ; 119 : 570-2.
PubMed
3) Lello J, Pearl A, Arroll B, et al. Prevalence of acne vulgaris in Auckland senior high school students. N Z Med J 1995 ; 108 : 287-9.
PubMed
4) Pearl A, Arroll B, Lello J, et al. The impact of acne : a study of adolescents' attitudes, perception and knowledge. N Z Med J 1998 ; 111 : 269-71.
PubMed
5) 林伸和, 川島眞, 渡辺晋一, ほか. 本邦における尋常性ざ瘡のアンケートによる疫学的調査成績. 日皮会誌 2001 ; 111 : 1347-55.
 
6) Kubota Y, Shirahige Y, Nakai K, et al. Community-based epidemiological study of psychosocial effects of acne in Japanese adolescents. J Dermatol 2010 ; 37 : 617-22.
PubMed
7) Fulton JE Jr, Plewig G, Kligman AM. Effect of chocolate on acne vulgaris. JAMA 1969 ; 210 : 2071-4.
PubMed
8) Anderson PC. Foods as the cause of acne. Am Fam Physician 1971 ; 3 : 102-3.
PubMed
9) Hamilton JB, Terada H, Mestler GE. Greater tendency to acne in white American than in Japanese populations. J Clin Endocrinol Metab 1964 ; 24 : 267-72.
PubMed
10) Cordain L. Implications for the role of diet in acne. Semin Cutan Med Surg 2005 ; 24 : 84-91.
PubMed
11) Goulden V, McGeown CH, Cunliffe WJ. The familial risk of adult acne : a comparison between first-degree relatives of affected and unaffected individuals. Br J Dermatol 1999 ; 141 : 297-300.
PubMed
12) Palatsi R, Oikarinen A. Hormonal analysis and delayed hypersensitivity reactions in identical twins with severe acne. Acta Derm Venereol 1979 ; 59 : 157-60.
PubMed
13) Walton S, Wyatt EH, Cunliffe WJ. Genetic control of sebum excretion and acne-a twin study. Br J Dermatol 1988 ; 118 : 393-6.
PubMed
14) 林伸和, 小林美咲, 細谷律子, ほか. ざ瘡患者における掻破行動の実態調査. 臨皮 2002 ; 56 : 387-91.
 
15) Sundstrom A, Alfredsson L, Sjolin-Forsberg G, et al. Association of suicide attempts with acne and treatment with isotretinoin : retrospective Swedish cohort study. BMJ 2010 ; 341 : c5812.
 

II 診断基準・鑑別診断

P.24 掲載の参考文献
1) Plewig G, Kligman AM. Acne and Rosacea. 2nd ed. Berlin : Springer-Verlag ; 1993. pp270-85.
 
2) Walton S, Wyatt E, Clunliffe WJ. Genetic control of sebum excretion and acne. Br J Dermatol 1988 ; 18 : 393-6.
 
3) 黒川一郎, 西嶋攝子. 付) 集簇性ざ瘡. 玉置邦彦, ほか編. 最新皮膚科学大系 17. 付属器・口腔粘膜の疾患. 東京 : 中山書店 ; 2003. pp127-8.
 
P.28 掲載の参考文献
1) Walsh JS, Farley JA. Fitzpatrick's Dermatology in General Medicine. 7th ed. New York : McGraw-Hill ; 2008. p701.
 
2) Karvonen SL. Acne fulminans : report of clinical findings and treatment of twenty-four patients. J Am Acad Dermatol 1993 ; 28 : 572-9.
PubMed
3) 林伸和, 赤松浩彦, 岩月啓氏, ほか. 尋常性ざ瘡治療ガイドライン. 日皮会誌 2008 ; 118 : 1893-923.
 
4) 山田晶子, 山崎修, 山本哲也, ほか. Acne fulminansの1例. 臨皮 2005 ; 59 : 872-5.
 
5) 黒川一郎, 西嶋攝子. 劇症ざ瘡. 玉置邦彦, ほか編. 最新皮膚科学大系 17. 付属器・口腔粘膜の疾患. 東京 : 中山書店 ; 2002. pp128-9.
 
6) Iqbal M, Kolodney MS. Acne fulminans with synovitis-acne-pustulosis-hyperostosis-osteitis (SAPHO) syndrome treated with infliximab. J Am Acad Dermatol 2005 ; 52 (5 Suppl 1) : S118-20.
 
7) McKee PH, Calonje E, Granter SR. Pathology of the Skin with Clinical Correlations. 3rd ed. Philadelphia : Elsevier Mosby ; 2005. p1120.
 
8) 餐場伸作, 向井秀樹. acne fulminans. 皮膚病診療 2005 ; 27 : 265-8.
 
P.32 掲載の参考文献
1) Berg M, Liden S. An epidemiological study of rosacea. Acta Derm Venereol 1989 ; 69 : 419-23.
PubMed
1) Crawford GH, Pelle MT, James WD. Rosacea : I. Etiology, pathogenesis, and subtype classification. J Am Acad Dermatol 2004 ; 51 : 327-41 ; quiz 342-4.
 
2) Wilkin J, Dahl M, Detmar M, et al. Standard classification of rosacea : report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol 2002 ; 46 : 584-7.
PubMed
3) Wilkin J, Dahl M, Detmar M, et al. Standard grading system for rosacea : report of the National Rosacea Society Expert Committee on the classification and staging of rosacea. J Am Acad Dermatol 2004 ; 50 : 907-12.
PubMed
P.37 掲載の参考文献
1) Odom R, Dahl M, Dover J, et al. Standard management options for rosacea, part 1 : overview and broad spectrum of care. Cutis 2009 ; 84 : 43-7.
PubMed
2) Odom R, Dahl M, Dover J, et al. Standard management options for rosacea, part 2 : options according to subtype. Cutis 2009 ; 84 : 97-104.
PubMed
3) Del Rosso JQ, Baldwin H, Webster G. American Acne & Rosacea Society rosacea medical management guidelines. J Drugs Dermatol 2008 ; 7 : 531-3.
PubMed
4) Wilkin JK. Use of topical products for maintaining remission in rosacea. Arch Dermatol 1999 ; 135 : 79-80.
PubMed
5) Wilkin JK. The red face : flushing disorders. Clin Dermatol 1993 ; 11 : 211-23.
PubMed
P.42 掲載の参考文献
1) 川上理子, 肥田野信. 新生児ざ瘡. 皮膚病診療 1979 ; 1 : 309-12.
 
2) 朝田康夫. 新生児ざ瘡. 坂元正一, 編. 産婦人科Mook 36. 婦人・新生児と皮膚疾患. 東京 : 金原出版 ; 1986. pp82-6.
 
3) Niamba P, Weill FX, Sarlangue J, et al. Is common neonatal cephalic pustulosis (neonatal acne) triggered by Malassezia sympodialis? Arch Dermatol 1998 ; 134 : 995-8.
PubMed
P.45 掲載の参考文献
1) 石崎純子. マラセチア. MB Derma 2004 ; 83 : 35-9.
 
2) 清佳浩. マラセチア毛包炎は夏季ざ瘡, ステロイドざ瘡と一緒か. 望月隆, ほか編. 皮膚科サブスペシャリティーシリーズ. 1冊でわかる皮膚真菌症. 東京 : 文光堂 ; 2008. p151.
 
3) 坪井良治. マラセチア属真菌とその関連皮膚疾患. 日皮会誌 2009 ; 119 : 163-71.
 
4) 五十嵐敦之. マラセチアが起こす皮膚疾患～脂漏性皮膚炎と毛包炎～. 望月 隆, ほか編. 皮膚科サブスペシャリティーシリーズ. 1冊でわかる皮膚真菌症. 東京 : 文光堂 ; 2008. pp148-9.
 
5) 清佳浩. Malassezia 関連疾患. 真菌誌 2006 ; 47 : 75-80.
 
6) 清佳浩. マラセチア毛包炎. 玉置邦彦, ほか編. 最新皮膚科学大系 14. 細菌・真菌性疾患. 東京 : 中山書店 ; 2003. pp262-4.
 
7) 清佳浩. Malassezia 関連疾患の臨床像, 診断. J Visual Dermatol 2008 ; 7 : 536-8.
 
8) 常深祐一郎. マラセチア毛包炎. 常深祐一郎. 毎日診ている皮膚真菌症. 東京 : 南山堂 ; 2010. pp154-5.
 
P.49 掲載の参考文献
1) 黒川一郎, 西嶋攝子. 毛包虫性ざ瘡. 玉置邦彦, ほか編. 最新皮膚科学大系 17. 付属器・口腔粘膜の疾患. 東京 : 中山書店 ; 2002. pp134-5.
 
2) 上野賢一, 大塚藤男. ニキビダニざ瘡. MINOR TEXTBOOK 皮膚科学. 第8版. 東京 : 金芳堂 ; 2006. p629.
 
3) 大滝倫子. ニキビダニ症. 玉置邦彦, ほか編. 最新皮膚科学大系 16. 動物性皮膚症 環境因子による皮膚障害. 東京 : 中山書店 ; 2003. pp67-9.
 
4) 小泉直人, 森原潔, 末廣晃宏, ほか. タクロリムス軟膏外用が悪化の誘因と考えられた皮膚毛包虫症の4例. 皮膚臨床 2006 ; 48 : 1185-8.
 
5) 滝脇弘嗣. 湿疹・眼瞼炎型毛包虫症の1例. 臨皮 2004 ; 58 : 754-6.
 
6) Karincaoglu Y, Bayram N, Aycan O, et al. The clinical importance of Demodex folliculorum presenting with nonspecific facial signs and symptoms. J Dermatol 2004 ; 31 : 618-26.
PubMed
P.53 掲載の参考文献
1) Patterson WM, Fox MD, Schwartz RA. Favre-Racouchot disease. Int J Dermatol 2004 ; 43 : 167-9.
PubMed
1) Lewis KG, Bercovitch L, Dill SW, et al. Acquired disorders of elastic tissue : part I. Increased elastic tissue and solar elastotic syndromes. J Am Acad Dermatol 2004 ; 51 : 1-21.
PubMed
2) Sharkey MJ, Keller RA, Grabski WJ, et al. Favre-Racouchot syndrome. A combined therapeutic approach. Arch Dermatol 1992 ; 128 : 615-6.
PubMed
3) 石川牧子, 江川裕美, 涌田あすか, ほか. 多房性嚢腫を呈したFavre-Racouchot症候群の1例. 皮膚臨床 2009 ; 51 : 385-8.
 
4) 関根亜希子, 漆畑修, 猿谷佳奈子, ほか. 老人性面皰とその治療 (ケミカルピーリング). Visual Dermatology 2006 ; 5 : 144-5.
 
5) Mavilia L, Campolmi P, Santoro G, et al. Combined treatment of Favre-Racouchot syndrome with a superpulsed carbon dioxide laser : report of 50 cases. Dermatol Ther 2010 ; 23 (Suppl 1) : S4-6.
 
6) Kaya TI, Tursen U, Yazici AC, et al. A simple open comedone extraction technique for Favre-Racouchot disease. Photodermatol Photoimmunol Photomed 2005 ; 21 : 275-7.
PubMed
7) Givan J, Hurley MY, Glaser DA. Nevus comedonicus : a novel approach to treatment. Dermatol Surg 2010 ; 36 : 721-5.
PubMed
8) 三宅亜矢子, 鈴木布衣子, 木花いづみ. 毛嚢嚢腫を合併した面皰母斑. 皮膚病診療 2003 ; 25 : 1111-4.
 
9) 遠藤英樹, 弓立達夫, 荒金兆典, ほか. 表皮嚢腫を伴った面皰母斑. 皮膚 2000 ; 42 : 188-91.
 
10) Happle R. The group of epidermal nevus syndromes Part I. Well defined phenotypes. J Am Acad Dermatol 2010 ; 63 : 1-22.
 
11) 安部万里絵, 岡田悦子, 永井弥生, ほか. 面皰母斑の1例. 臨皮 2006 ; 60 : 805-7.
 
12) Decherd JW, Mills O, Leyden JJ. Naevus comedonicus-treatment with retinoic acid. Br J Dermatol 1972 ; 86 : 528-9.
PubMed
13) Wakahara M, Kiyohara T, Kumakiri M, et al. Bilateral nevus comedonicus : efficacy of topical tacalcitol ointment. Acta Derm Venereol 2003 ; 83 : 51.
PubMed
14) Caers SJ, Van der Geer S, Beverdam EG, et al. Successful treatment of nevus comedonicus with the use of the Erbium Yag laser. J Eur Acad Dermatol Venereol 2008 ; 22 : 375-7.
PubMed
P.57 掲載の参考文献
1) Nanney LB, McKanna JA, Stoscheck CM, et al. Visualization of epidermal growth factor receptors in human epidermis. J Invest Dermatol 1984 ; 83 : 385-93.
 
2) Surguladze D, Deevi D, Claros N, et al. Tumor necrosis factor-α and interleukin-1 antagonists alleviate inflammatory skin changes associated with epidermal growth factor receptor antibody therapy in mice. Cancer Res 2009 ; 69 : 5643-7.
 
3) Agero AL, Dusza SW, Benvenuto-Andrade C, et al. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol 2006 ; 55 : 657-70.
PubMed
4) 古田淳一, 藤澤康広, 伊藤倫子, ほか. エルロチニブによる薬疹の2例. 皮膚臨床 2010 ; 52 : 303-6.
 
5) Perez-Soler R, Chachoua A, Hammond LA, et al. Determinants of tumor response and survival with erlotinib in patients with non-small cell lung cancer. J Clin Oncol 2004 ; 22 : 3238-47.
PubMed
6) Jacot W, Besis D, Jorda E, et al. Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours. Br J Dermatol 2004 ; 151 : 238-41.
 
7) 白藤宣紀, 濱田利久, 大野貴司, ほか. エルロチニブによる皮膚症状とその治療. 皮膚臨床 2010 ; 52 : 297-302.
 
P.61 掲載の参考文献
1) 狩野葉子. 薬剤がもたらす皮膚病変 抗がん剤による皮膚病変. 医薬ジャーナル 2008 ; 44 : 2709-12.
 
P.63 掲載の参考文献
1) Chen W, Obermayer-Pietsch B, Hong JB, et al. Acne-associated syndromes : models for better understanding of acne pathogenesis. J Eur Acad Dermatol Venereol 2011 ; 25 : 637-46.
PubMed
1) Stein IF, Leventhal ML. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 1935 ; 29 : 181-91.
 
2) 杉本修, 青野敏博, 森崇英, ほか. 生殖・内分泌委員会報告 : 本邦婦人における多嚢胞性卵巣症候群の診断基準設定に関する小委員会 (平成2年度～平成4年度) 検討結果報告. 日産婦誌 1993 ; 45 : 1359-67.
 
3) Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004 ; 81 : 19-25.
 
4) Iwasa T, Matsuzaki T, Tanaka N, et al. Comparison and problems of measured values of LH, FSH and PRL among measurement systems. Endocr J 2006 ; 53 : 101-9.
PubMed
5) 水沼英樹, 苛原稔, 久具宏司, ほか. 本邦における多嚢胞性卵巣症候群の新しい診断基準の設定に関する小委員会 (平成17年度～平成18年度) 検討結果報告. 日産婦誌 2007 ; 59 : 1364-83.
 
6) 久保田俊郎, 苛原稔, 小辻文和, ほか. 生殖・内分泌委員会報告「本邦における多嚢胞性卵巣症候群の治療法に関する治療指針作成のための小委員会」報告. 日産婦誌 2009 ; 61 : 902-12.
 
7) Messina M, Manieri C, Musso MC, et al. Oral and topical spironolactone therapies in skin androgenization. Panminerva Med 1990 ; 32 : 49-55.
PubMed
8) Yamamoto A, Ito M. Topical spironolactone reduces sebum secretion rates in young adults. J Dermatol 1996 ; 23 : 243-6.
PubMed
9) Sato K, Matsumoto D, Iizuka F, et al. Anti-androgenic therapy using oral spironolactone for acne vulgaris in Asians. Aesthetic Plast Surg 2006 ; 30 : 689-94.
PubMed
P.70 掲載の参考文献
1) Ofuji S, Ogino A, Horio T, et al. Eosinophilic pustular folliculitis. Acta Derm Venereol 1970 ; 50 : 195-203.
PubMed
2) Ishiguro N, Shishido E, Okamoto R, et al. Ofuji's disease : a report on 20 patients with clinical and histopathologic analysis. J Am Acad Dermatol 2002 ; 46 : 827-33.
PubMed
3) Nishijima S, Sugiyama T, Nakagawa M, et al. Two cases of eosinophilic pustular folliculitis treated by Acemetacin. J Dermatol 1994 ; 21 : 779-82.
PubMed
P.74 掲載の参考文献
1) Shelley WB, Kligman AM. The experimental production of acne by penta and hexachloronaphthalenes. Arch Dermatol 1957 ; 75 : 689-95.
 
2) Hambrick GW. The effect of substituted naphthalenes on the pilosebaceous apparatus of rabbit and man. J Invest Dermatol 1957 ; 28 : 89-102.
 
3) Tauchi M, Hida A, Negishi T, et al. Constitutive expression of aryl hydrocarbon receptor in keratinocytes causes inflammatory skin lesions. Mol Cell Biol 2005 ; 25 : 9360-8.
PubMed
4) Geusau A, Khorchide M, Mildner M, et al. 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin impairs differentiation of normal human epidermal keratinocytes in a skin equivalent model. J Invest Dermatol 2004 ; 124 : 275-7.
 

III 病因論・病態・病理

P.78 掲載の参考文献
1) 黒川一郎, 西嶋攝子. 尋常性ざ瘡. 玉置邦彦, ほか編. 最新皮膚科学大系 17. 付属器・口腔粘膜の疾患. 東京 : 中山書店 ; 2002. pp117-26.
 
2) 古川福実. EBMを活かしたニキビの治療と展望. 古川福実, ほか編. 皮膚科診療プラクティス 18. ニキビ治療の技法. 東京 : 文光堂 ; 2005. pp2-8.
 
3) 宮地良樹. ニキビの二面性を知る. 古川福実, ほか編. 皮膚科診療プラクティス 18. ニキビ治療の技法. 東京 : 文光堂 ; 2005. pp48-52.
 
4) 檜垣修一. ニキビの病態. MB Derma 2001 ; 49 : 8-12.
 
5) 上出康二. 毛包はなぜつまる? 古川福実, ほか編. 皮膚科診療プラクティス 18. ニキビ治療の技法. 東京 : 文光堂 ; 2005. pp25-31.
 
6) 船坂陽子. ざ瘡 (にきび). 日本美容皮膚科学会, 編. 美容皮膚科学. 改訂2版. 東京 : 南山堂 ; 2009. pp579-90.
 
7) Furukawa F, Ohshio G, Kao T-C, et al. Pathogenicity of Propionibacterium acnes (Kato) isolated from the patient with mucocutaneous lymph node syndrome. Acta Dermatol (Kyoto) 1986 ; 81 : 385-94.
 
8) 岡本裕之. P. acnesとサルコイドーシス. 古川福実, ほか編. 皮膚科診療プラクティス 18. ニキビ治療の技法. 東京 : 文光堂 ; 2005. pp39-40.
 
9) 小林美和. サイトカイン/ケモカイン. 戸倉新樹, 編. ファーストステップ皮膚免疫学. 東京 : 中外医学社 ; 2010. pp52-61.
 
10) 佐山浩二. 自然免疫. 戸倉新樹, 編. ファーストステップ皮膚免疫学. 東京 : 中外医学社 ; 2010. pp62-73.
 
P.83 掲載の参考文献
1) 伊藤雅章, 山本綾子. 脂腺の構造と機能. 皮膚臨床 1996 ; 38 : 853-62.
 
2) Cunliffe WJ. Acne. London : Martin Dunitz ; 1989. pp93-114.
 
3) Brandes D, Beritini F. Role of lysosomes in cellular lytic processes. II. Cell death during holocrine secretion in sebaceous glands. Exp Mol Pathol 1965 ; 4 : 245-65.
 
4) Ito M, Motoyoshi K, Suzuki M, et al. Sebaceous gland hyperplasia on rabbit pinna induced by tetradecane. J Invest Dermatol 1985 ; 85 : 249-54.
PubMed
5) Motoyoshi K, Ito M, Sakamoto F, et al. A time course study of the proliferation of sebaceous glands induced by topically applied tetradecane in rabbit pinna skin : autoradiography and electron microscopy. J Dermatol 1987 ; 14 : 9-14.
 
6) Plewig G, Christophers E. Renewal rate of human sebaceous glands. Acta Derm Venereol (Stockh) 1974 ; 54 : 177-82.
PubMed
7) 増子倫樹. 女性における脂腺の年齢による形態変化 : 画像解析と電顕による研究. 日皮会誌 1988 ; 98 : 443-52.
 
8) 池田和人. 男性における脂腺の年齢による形態変化. 日皮会誌 1991 ; 101 : 421-6.
 
9) Stewart ME, Downing DT. Chemistry and function of mammalian sebaceous lipids. Adv Lipid Res 1991 ; 24 : 263-301.
PubMed
10) 鈴木智. マイボーム腺と性ホルモン. あたらしい眼科 2001 ; 18 : 287-92.
Medical*Online
11) 山口昌彦. マイボーム腺の臨床所見. あたらしい眼科 2001 ; 18 : 293-9.
Medical*Online
12) 山本綾子, 芹沢重男, 伊藤雅章, ほか. 皮脂と老化. 日皮会誌 1991 ; 101 : 1650-2.
 
13) Watanabe R, Fujii H, Odani S, et al. Molecular cloning of a cDNA encoding a novel fatty acid-binding protein from rat skin. Biochem Biophys Res Commun 1994 ; 200 : 253-9.
PubMed
14) Watanabe R, Fujii H, Yamamoto A, et al. Immunohistochemical distribution of cutaneous fatty acid-binding protein in human skin. Arch Dermatol Res 1997 ; 16 : 17-22.
 
15) Merrill B, Gat U, DasGupta R, et al. Tcf3 and Lef1 regulate lineage differentiation of multipotent stem cells in skin. Genes Dev 2001 ; 15 : 1688-705.
PubMed
16) Niemann C, Unden A, Lyle S, et al. Indian hedgehog and beta-catenin signaling : role in the sebaceous lineage of normal and neoplastic mammalian epidermis. Proc Natl Acad Sci U S A 2003 ; 100 (Suppl 1) : 11873-80.
 
17) Allen M, Grachtchouk M, Sheng H, et al. Hedgehog signaling regulates sebaceous gland development. Am J Pathol 2003 ; 163 : 2173-8.
PubMed
18) Arnold I, Watt F. c-Myc activation in transgenic mouse epidermis results in mobilization of stem cells and differentiation of their progeny. Curr Biol 2001 ; 11 : 558-68.
 
19) Waikel R, Kawachi Y, Waikel P, et al. Deregulated expression of c-Myc depletes epidermal stem cells. Nat Genet 2001 ; 28 : 165-8.
PubMed
20) Jiang YJ, Lu B, Kim P, et al. PPAR and LXR activators regulate ABCA12 expression in human keratinocytes. J Invest Dermatol 2008 ; 128 : 104-9.
PubMed
21) Schmuth M, Elias PM, Hanley K, et al. The effect of LXR activators on AP-1 proteins in keratinocytes. J Invest Dermatol 2004 ; 123 : 41-8.
PubMed
22) Yen CL, Monetti M, Burri J, et al. The triacylglycerol synthesis enzyme DGAT1 also catalyzes the synthesis of diacylglycerols, waxes, and retinyl esters. J Lipid Res 2005 ; 46 : 1502-11.
 
23) Harrison WJ, Bull JJ, Seltmann H, et al. Expression of lipogenic factors galectin-12, resistin, SREBP-1 and SCD in human sebaceous glands and cultured sebocytes. J Invest Dermatol 2007 ; 127 : 1309-17.
PubMed
24) Smith TM, Cong Z, Gilliland KL, et al. Insulin-like growth factor-1 induces lipid production in human SEB-1 sebocytes via sterol response element binding protein-1. J Invest Dermatol 2006 ; 126 : 1226-32.
PubMed
25) Thielitz A, Reinhold D, Vetter R, et al. Inhibitors of dipeptidyl peptidase IV (DPIV, CD26) and aminopeptidase N (APN, CD13) target major pathogenetic steps in acne initiation. J Invest Dermatol 2007 ; 127 : 1042-51.
 
26) Thiboutot D, Sivarajah A, Gilliland K, et al. The melanocortin 5 receptor is expressed in human sebaceous glands and rat preputial cells. J Invest Dermatol 2000 ; 115 : 614-9.
 
27) Zhang L, Li WH, Anthonavage M, et al. Melanocortin-5 receptor : a marker of human sebocyte differentiation. Peptides 2006 ; 27 : 413-20.
 
P.90 掲載の参考文献
1) Youn SW, Park ES, Lee DH, et al. Does facial sebum excretion really affect the development of acne? Br J Dermatol 2005 ; 153 : 919-24.
PubMed
1) Zouboulis CC. Sebaceous gland receptors. Dermatoendocrinol 2009 ; 1 : 77-80.
PubMed
2) Akamatsu H, Zouboulis CC, Orfanos CE. Control of human sebocyte proliferation in vitro by testosterone and 5-alpha-dihydrotestosterone is dependent on the localization of the sebaceous glands. J Invest Dermatol 1992 ; 99 : 509-11.
PubMed
3) Makrantonaki E, Zouboulis CC. Testosterone metabolism to 5 alpha-dihydrotestosterone and synthesis of sebaceous lipids is regulated by the peroxisome proliferator-activated receptor ligand linoleic acid in human sebocytes. Br J Dermatol 2007 ; 156 : 428-32.
PubMed
4) Chen W, Tsai SJ, Sheu HM, et al. Testosterone synthesized in cultured human SZ95 sebocytes derives mainly from dehydroepiandrosterone. Exp Dermatol 2010 ; 19 : 470-2.
 
5) Thiboutot D, Martin P, Volikos L, et al. Oxidative activity of the type 2 isozyme of 17 beta-hydroxysteroid dehydrogenase (17β-HSD) predominates in human sebaceous glands. J Invest Dermatol 1998 ; 111 : 390-5.
 
6) Lee WJ, Jung HD, Chi SG, et al. Effect of dihydrotestosterone on the upregulation of inflammatory cytokines in cultured sebocytes. Arch Dermatol Res 2010 ; 302 : 429-33.
PubMed
P.94 掲載の参考文献
1) 林伸和, 川島眞, 渡辺晋一, ほか. 本邦における尋常性ざ瘡のアンケートによる疫学的調査成績. 日皮会誌 2001 ; 111 : 1347-55.
 
2) Kubota Y, Shirahige Y, Nakai K, et al. Community-based epidemiological study of psychosocial effects of acne in Japanese adolescents. Journal of Dermatology 2010 ; 37 : 617-22.
PubMed
3) Lucky AW. Quantitative documentation of a premenstrual flare of facial acne in adult women. Arch Dermatol 2004 ; 140 : 423-4.
PubMed
4) 三宅侃. 性成熟期の正常内分泌学. 中村幸雄, ほか編. 図説産婦人科VIEW 6. 内分泌検査法. 東京 : メジカルビュー社 ; 1944. pp28-39.
 
5) Thiboutot D, Gilliland K, Light J, et al. Androgen metabolism in sebaceous glands from subjects with and without acne. Arch Dermatol 1999 ; 135 : 1041-5.
PubMed
6) Arora MK, Seth S, Dayal S. The relationship of lipid profile and menstrual cycle with acne vulgaris. Clin Biochem 2010 ; 43 : 1415-20.
PubMed
7) Chen WC, Zouboulis CC. Hormones and the pilosebaceous unit. Dermatoendocrinol 2009 ; 1 : 81-6.
PubMed
P.97 掲載の参考文献
1) Kurokawa I, Danby FW, Ju Q, et al. New developments in our understanding of acne pathogenesis and treatment. Exp Dermatol 2009 ; 18 : 821-32.
PubMed
1) Cunliffe WJ, Holland DB, Clark SM, et al. Comedogenesis : some aetiological, clinical and therapeutic strategies. Dermatology 2003 ; 206 : 11-6.
PubMed
2) Plewig G, Kligman AM. Acne & Rosacea. 4th ed. Berlin : Springer-Verlag ; 2005.
 
3) Knutson DD. Ultrastructural observations in acne vulgaris : the normal sebaceous follicle and acne lesions. J Invest Dermatol 1974 ; 62 : 288-307.
PubMed
4) Dale BA, Holbrook KA, Steinert PM. Assembly of stratum corneum basic protein and keratin filaments in macrofibrils. Nature 1978 ; 276 : 729-31.
PubMed
5) Kurokawa I, Mayer-da-Silva A, Gollnick H, et al. Monoclonal antibody labeling for cytokeratins and filaggrin in the human pilosebaceous unit of normal, seborrhoeic and acne skin. J Invest Dermatol 1988 ; 91 : 566-71.
PubMed
6) Kurokawa I, Umeda K, Nishimura K, et al. Filaggrin expression and the pathogenesis of epidermal cysts. Br J Dermatol 2007 ; 157 : 415-6.
PubMed
7) Kurokawa I, Nakai Y, Nishimura K, et al. Cytokeratin and filaggrin expression in nevus comedonicus. J Cutan Pathol 2007 ; 34 : 338-41.
PubMed
8) Hughes BR, Morris C, Cunliffe WJ, et al. Keratin expression in pilosebaceous epithelia in truncal skin of acne patients. Br J Dermatol 1996 ; 134 : 247-56.
PubMed
9) Knaggs HE, Holland DB, Morris C, et al. Quantification of cellular proliferation in acne using the monoclonal antibody Ki-67. J Invest Dermatol 1994 ; 102 : 89-92.
PubMed
10) Knaggs HE, Hughes BR, Morris C, et al. Immunohistochemical study of desmosomes in acne vulgaris. Br J Dermatol 1994 ; 130 : 731-7.
PubMed
11) Knaggs HE, Layton AM, Morris C, et al. Investigation of the expression of the extracellular matrix glycoproteins tenascin and fibronectin during acne vulgaris. Br J Dermatol 1994 ; 130 : 576-82.
PubMed
12) Ingham E, Eady EA, Goodwin CE, et al. Pro-inflammatory levels of interleukin-1 alpha-like bioactivity are present in the majority of open comedones in acne vulgaris. J Invest Dermatol 1992 ; 98 : 895-901.
PubMed
13) Guy R, Green MR, Kealey T. Modeling acne in vitro. J Invest Dermatol 1996 ; 106 : 176-82.
PubMed
14) Thiboutot DM, Knaggs H, Gilliland K, et al. Activity of type 1 5 alpha-reductase is greater in the follicular infrainfundibulum compared with the epidermis. Br J Dermatol 1997 ; 136 : 166-71.
PubMed
15) Downing DT, Stewart ME, Wertz PW, et al. Essential fatty acids and acne. J Am Acad Dermatol 1986 ; 14 : 221-5.
PubMed
16) Saint-Leger D, Bague A, Lefebvre E, et al. A possible role for squalene in the pathogenesis of acne. II. In vivo study of squalene oxides in skin surface and intra-comedonal lipids of acne patients. Br J Dermatol 1986 ; 114 : 543-52.
 
17) Letawe C, Boone M, Pierard GE. Digital image analysis of the effect of topically applied linoleic acid on acne microcomedones. Clin Exp Dermatol 1998 ; 23 : 56-8.
PubMed
18) Puhvel SM, Sakamoto M. A reevaluation of fatty acids as inflammatory agents in acne. J Invest Dermatol 1977 ; 68 : 93-7.
 
19) Jarrousse V, Castex-Rizzi N, Khammari A, et al. Modulation of integrins and filaggrin expression by Propionibacterium acnes extracts on keratinocytes. Arch Dermatol Res 2007 ; 299 : 441-7.
PubMed
20) Plewig G, Fulton JE, Kligman AM. Cellular dynamics of comedo formation in acne vulgaris. Arch Dermatol Forsch 1971 ; 242 : 12-29.
PubMed
21) Zouboulis CC, Eady A, Philpott M, et al. What is the pathogenesis of acne? Exp Dermatol 2005 ; 14 : 143-52.
PubMed
22) Jeremy AH, Holland DB, Roberts SG, et al. Inflammatory events are involved in acne lesion initiation. J Invest Dermatol 2003 ; 121 : 20-7.
PubMed
23) Melnik B, Schmitz G. FGFR2 signaling and the pathogenesis of acne. J Dtsch Dermatol Ges 2008 ; 6 : 721-8.
PubMed
P.103 掲載の参考文献
1) 赤松浩彦. ニキビ (尋常性ざ瘡) の臨床とその発症機序. Visual Dermatology 2003 ; 2 : 223-6.
 
2) 朝田康夫. にきび (尋常性ざ瘡). 東京 : 金原出版 ; 1983.
 
3) Pochi PE. Acne : androgens and microbiology. Drug Dev Res 1988 ; 13 : 157-68.
 
4) 西嶋攝子, 黒川一郎, 赤松浩彦. ざ瘡の発症機序. 朝田康夫, ほか編. 尋常性ざ瘡. 東京 : 協和企画 ; 1993. pp29-48.
 
5) 赤松浩彦, 朝田康夫. ざ瘡. 久木田淳, ほか編. 皮膚感染症の診療のてびき. 東京 : 臨床医薬研究協会 ; 1999. pp7-24.
 
6) 丹羽靭負, 宗宮教壹. 生体の活性酸素とsuperoxide dismutaseに関連した疾患群およびその治療について. 最新医学 1984 ; 39 : 339-56.
 
7) 丹羽靭負. 炎症と活性酸素. リウマチ 1983 ; 23 : 237-53.
 
8) 赤松浩彦. 尋常性ざ瘡における好中球活性酸素の意義. マルホ皮膚科セミナー 1996 ; 123 : 24-7.
 
9) 赤松浩彦, 丹羽靭負, 堀尾武. clindamycinの抗炎症作用機序の検討. 皮膚科紀要 1998 ; 93 : 35-9.
 
10) 赤松浩彦, 朝田康夫, 丹羽靭負. ざ瘡に対する荊芥連翹湯の奏効機序の検討-活性酸素に及ぼす影響について. 漢方医学 1994 ; 18 : 51-4.
 
11) Pye RJ, Burton JL. Treatment of rosacea by metronidazole. Lancet 1976 ; 307 (7971) : 1211-2.
 
12) Miyachi Y, Imamura S, Niwa Y. Anti-oxidant action of metronidazole : a possible mechanism of action of rosacea. Br J Dermatol 1986 ; 114 : 231-4.
PubMed
13) Akamatsu H, Oguchi M, Nishijima S, et al. The inhibition of free radical generation by human neutrophils through the synergistic effects of metronidazole with palmitoleic acid : a possible mechanism of action of metronidazole in rosacea and acne. Arch Dermatol Res 1990 ; 282 : 449-54.
PubMed
14) 尾口基, 赤松浩彦, 朝田真木, ほか. Metronidazoleによるざ瘡の治療. 皮膚 1987 ; 29 : 995-1000.
 
15) Perisho K, Wertz PW, Madison KC, et al. Fatty acids of acylceramides from comedones and from the skin surface of acne patients and control subjects. J Invest Dermatol 1988 ; 90 : 350-3.
PubMed
16) Akamatsu H, Komura J, Miyachi Y, et al. Suppressive effects of linoleic acid on neutrophil oxygen metabolism and phagocytosis. J Invest Dermatol 1990 ; 95 : 271-4.
PubMed
17) Akamatsu H, Horio T, Hattori K. Increased hydrogen peroxide generation by neutrophils from patients with acne inflammation. Int J Dermatol 2003 ; 42 : 366-9.
PubMed
18) Kim J, Ochoa MT, Krutzik SR, et al. Activation of toll-like receptor 2 in acne triggers inflammatory cytokine responses. J Immunol 2002 ; 169 : 1535-41.
PubMed
19) Jugeau S, Tenaud I, Knol AC, et al. Induction of toll-like receptors by Propionibacterium acnes. Br J Dermatol 2005 ; 153 : 1105-13.
PubMed
20) Miyachi Y, Horio T, Imamura S. Sunburn cell formation is prevented by scavenging oxygen intermediates. Clin Exp Dermatol 1983 ; 8 : 305-10.
PubMed
21) Masaki H, Atsumi T, Sakurai H. Detection of hydrogen peroxide and hydroxyl radicals in murine skin fibroblasts under UVB irradiation. Biochem Biophys Res Commun 1995 ; 206 : 474-9.
PubMed
22) Tyrrell RM, Pidoux M. Singlet oxygen involvement in the inactivation of cultured human fibroblasts by UVA (334nm, 365nm) and near-visible (405nm) radiations. Photochem Photobiol 1989 ; 49 : 407-12.
 
23) Motohashi K. Enhanced comedo formation in rabbit ear skin. Br J Dermatol 1983 ; 109 : 191-8.
 
24) Mills OT, Porte M, Kligman AM. Enhancement of comedogenic substances by ultraviolet radiation. Br J Dermatol 1978 ; 98 : 145-50.
 
25) 船坂陽子, 市橋正光. 紫外線と活性酸素. 佐藤吉昭, 監. 光線過敏症. 第3版. 東京 : 金原出版 ; 2002. pp65-73.
 
26) Arakane K, Ryu A, Hayashi C, et al. Singlet oxygen (1Δg) generation from coproporphyrin in Propionibacterium acnes on irradiation. Biochem Biophys Res Commun 1996 ; 223 : 578-82.
 
27) Cunliffe WJ, Simpson NB. Disorders of the sebaceous glands. In : Champion RN, et al, editors. Textbook of Dermatology. 6th ed. Oxford : Blackwell Science ; 1998. pp1927-84.
 
28) Layton AM, Morris C, Cunliffe WJ, et al. Immunohistochemical investigation of evolving inflammation in lesions of acne vulgaris. Exp Dermatol 1998 ; 7 : 191-7.
PubMed
P.109 掲載の参考文献
1) Jacob Cl, Dover JS, Kaminer MS. Acne scarring : a classification system and review of treatment options. J Am Acad Dermatol 2001 ; 45 : 109-17.
 
2) Holland DB, Jeremy AH, Roberts SG, et al. Inflammation in acne scarring : a comparison of the responses in lesions from patients prone and not prone to scar. Br J Dermatol 2004 ; 150 : 72-81.
 
3) Trivedi NR, Gilliland KL, Zhao W, et al. Gene array expression profiling in acne lesions reveals marked upregulation of genes involved in inflammation and matrix remodeling. J Invest Dermatol 2006 ; 126 : 1071-9.
PubMed
4) Jalian HR, Liu PT, Kanchanapoomi M, et al. All-trans retinoic acid shifts Propionibacterium acnes-induced matrix degradation expression profile toward matrix preservation in human monocytes. J Invest Dermatol 2008 ; 128 : 2777-82.
PubMed
5) Batra S, Chen C, Rohrer TE. Scar management : keloid, hypertrophic, atrophic, and acne scars. In : Atlas of Cosmetic Surgery. Kaminer MS, et al, editors. Philadelphia : Saunders Elsevier ; 2009.
 
6) Goodman GJ, Baron JA. The management of postacne scarring. Dermatol Surg 2007 ; 33 : 1175-88.
PubMed
7) Rivera AE. Acne scarring : a review and current treatment modalities. J Am Acad Dermatol 2008 ; 59 : 659-76.
PubMed
8) 須賀康. フラクショナルレーザー療法の実際 : その基礎と応用について. 日レ医誌 2010 ; 31 : 65-71.
 
9) 春名邦隆, 須賀康. 瘢痕治療のコツ-陥凹性瘢痕に対する治療. MB Derma 2010 ; 170 : 55-61.
 
10) 黒川一郎, 西嶋攝子, 楠本健司. ざ瘡およびその類症の治療. 日本医事新報 2000 ; 3970 : 27-32.
 

IV 検査

P.114 掲載の参考文献
1) Hayashi N, Akamatsu H, Kawashima M, et al. Establishment of grading criteria for acne severity. J Dermatol 2008 ; 35 : 255-60.
PubMed
2) 林伸和, 赤松浩彦, 岩月啓氏, ほか. 尋常性ざ瘡治療ガイドライン. 日皮会誌 2008 ; 118 : 1893-923.
 
3) Plewig G, Kligman AM. Classification of acne vulgaris. In : Acne Morphogenesis and Treatment. Berlin : Springer-Verlag ; 1974. pp162-3.
 
4) Doshi A, Zaheer A, Stiller M. A comparison of current acne grading systems and proposal of a novel system. Int J Dermatol 1997 ; 36 : 416-8.
PubMed
5) O'Brien SC, Lewis JB, Cunliffe WJ. The Leeds revised acne grading system. J Dermatolog Treat 1998 ; 9 : 215-20.
 
6) Tan JK, Tang J, Fung K, et al. Development and validation of a comprehensive acne severity scale. J Cutan Med Surg 2007 ; 11 : 211-6.
PubMed
P.118 掲載の参考文献
1) Nakai K, Motten AG, Chignell CF. An in vivo study of free radicals generated in murine skin by protporphyrine IX and visible light. Photochem Photobiol 2006 ; 82 : 738-40.
 
2) Lucchina LC, Kollias N, Gillies R, et al. Fluorescence photography in the evaluation of acne. J Am Acad Dermatol 1996 ; 35 : 58-63.
PubMed
3) 窪田泰夫, 松岡由恵, 中井浩三, ほか. 成人女性ざ瘡患者を対象としたスキンケア製品の使用経験と皮膚生理機能および患者QOLに及ぼす影響. 西日皮膚 2008 ; 70 : 429-35.
 
4) Fujii H, Yanagisawa T, Mitsui M, et al. Extraction of acne lesion in acne patients from multispectral images. Conf Proc IEEE Eng Med Biol Soc 2008 ; 2008 : 4078-81.
 
P.122 掲載の参考文献
1) Whiteside JA, Voss JG. Incidence and lipolytic activity of Propionibacterium acnes (Corynebacterium acnes group I) and P. granulosum (C. acnes group II) in acne and in normal skin. J Invest Dermatol 1973 ; 60 : 94-7.
 
2) Celig DM, Schreckenberger PC. Clinical evaluation of the RapID-ANA II panel for identification of anaerobic bacteria. J Clin Microbiol 1991 ; 29 : 457-62.
PubMed
3) Williamson P, Kligman AM. A new method for the quantitative investigation of cutaneous bacteria. J Invest Dermatol 1965 ; 45 : 498-503.
PubMed
4) Holland KT, Roberts CD. A technique for sampling micro-organisms from the pilosebaceous ducts. J Appl Bacteriol 1974 ; 37 : 289-96.
PubMed
5) Leyden JJ, McGinley KJ, Mills OH, et al. Propionibacterium levels in patients with and without acne vulgaris. J Invest Dermatol 1975 ; 65 : 382-4.
PubMed
6) 日本化学療法学会. 嫌気性菌の最小発育阻止濃度 (MIC) 測定法. Chemotherapy 1979 ; 27 : 559-61.
 
7) Clinical and Laboratory Standards Institute. Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria ; Approved Standard-Fifth Edition. M11-A5, 2001.
 
8) 抗菌薬感受性測定法検討委員会. 寒天平板希釈法によるMIC測定法. 日本化学療法学会雑誌 2008 ; 56 : 49-57.
 
9) Ishida N, Nakaminami H, Noguchi N, et al. Antimicrobial susceptibilities of Propionibacterium acnes isolated from patients with acne vulgaris. Microbiol Immunol 2008 ; 52 : 621-4.
PubMed
10) Ross JI, Snelling AM, Eady EA, et al. Phenotypic and genotypic characterization of antibiotic-resistant Propionibacterium acnes isolated from acne patients attending dermatology clinics in Europe, the U.S.A., Japan and Australia. Br J Dermatol 2001 ; 144 : 339-46.
 
11) Kurokawa I, Nishijima S, Asada Y. The antibiotic susceptibility of Propionibacterium acnes : a 15-year bacteriological study and retrospective evaluation. J Dermatol 1988 ; 15 : 149-54.
PubMed
12) Kurokawa I, Akamatsu H, Nishijima S, et al. Clinical and bacteriologic evaluation of OPC-7251 in patients with acne : a double-blind group comparison study versus cream base. J Am Acad Dermatol 1991 ; 25 : 674-81.
 
13) Kurokawa I, Nishijima S, Kawabata S. Antimicrobial susceptibility of Propionibacterium acnes isolated from acne vulgaris. Eur J Dermatol 1999 ; 9 : 25-8.
PubMed
14) Eady EA, Cove JH, Holland KT, et al. Erythromycin resistant propionibacteria in antibiotic treated acne patients : association with therapeutic failure. Br J Dermatol 1989 ; 121 : 51-7.
PubMed
15) Kuwahara K, Kitazawa T, Kitagaki H, et al. Nadifloxacin, an antiacne quinolone antimicrobial, inhibits the production of proinflammatory cytokines by human peripheral blood mononuclear cells and normal human keratinocytes. J Dermatol Sci 2005 ; 38 : 47-55.
PubMed
P.129 掲載の参考文献
1) Kobayashi H, Tagami H. Distinct locational differences observable in biophysical functions of the facial skin : with special emphasis on the poor functional properties of the stratum corneum of the perioral region. Int J Cosmet Sci 2004 ; 26 : 91-101.
PubMed
1) Rogiers V. EEMCO guidance for the assessment of transepidermal water loss in cosmetic sciences. Skin Pharmacol Appl Skin Physiol 2001 ; 14 : 117-28.
PubMed
2) Pierard GE, Pierard-Franchimont C, Marks R, et al. EEMCO guidance for the in vivo assessment of skin greasiness. The EEMCO Group. Skin Pharmacol Appl Skin Physiol 2000 ; 13 : 372-89.
PubMed
2) Kikuchi K, Kobayashi H, Le Fur I, et al. Winter season affects more severely the facial skin than the forearm skin : comparative biophysical studies conducted in the same Japanese females in later summer and winter. Exo Dermatol 2002 ; 1 : 32-8.
 
3) Pagnoni A, Kligman AM, el Gammal S, et al. Determination of density of follicles on various regions of the face by cyanoacrylate biopsy : correlation with sebum output. Br J Dermatol 1994 ; 131 : 862-5.
PubMed
4) Yamamoto A, Takenouchi K, Ito M. Impaired water barrier function in acne vulgaris. Arch Dermatol Res 1995 ; 287 : 214-8.
PubMed
P.134 掲載の参考文献
1) Mills OH, Kligman AM. A human model for assessing comedogenic substances. Arch Dermatol 1982 ; 118 : 903-5.
PubMed
2) Mills OH, Kligman AM. The follicular biopsy. Dermatologica 1983 ; 167 : 57-63.
PubMed
P.137 掲載の参考文献
1) Barth JM, Yasmin E, Balan AH. The diagnosis of polycystic ovary syndrome : the criteria are insufficiently robust for clinical research. Clin Endocrinol (Oxf) 2007 ; 67 : 811-5.
 
2) 相原良子, 岡野由利, 赤松浩彦, ほか. 尋常性ざ瘡患者の発症機序におけるdehydroepiandrosterone の関与について. 日皮会誌 2003 ; 113 : 1-8.
 
3) 相澤浩. ざ瘡とステロイドホルモン. MB Derma 2000 ; 34 : 13-22.
 
4) 相澤浩, 新村眞人. 月経異常を伴った女性ざ瘡患者の血中ホルモン動態について. 皮膚 1996 ; 38 : 31-5.
 
5) 相澤浩. 尋常性ざ瘡におけるホルモンの意義. 第3回アクネ研究懇話会記録集. 1995. pp25-30.
 
P.142 掲載の参考文献
1) Feldman W, Hodgson C, Corber S, et al. Health concerns and health-related behaviours of adolescents. CMAJ 1986 ; 134 : 489-93.
PubMed
2) Lasek RJ, Chren MM. Acne vulgaris and the quality of life of adult dermatology patients. Arch Dermatol 1998 ; 134 : 454-8.
PubMed
3) 福原俊一, 編. 皮膚疾患のQOL評価-DLQI Skindex 29日本語版マニュアル. 京都 : 健康医療評価機構 (i Hope) ; 2004.
 
4) Hayashi N, Higaki Y, Kawamoto K, et al. A Cross-sectional analysis of quality of life in Japanese acne patients using the Japanese version of Skindex-16. J Dermatol 2004 ; 31 : 971-6.
PubMed
5) Jones-Caballero M, Chren MM, Soler B, et al. Quality of life in mild to moderate acne : relationship to clinical severity and factors influencing change with treatment. J Eur Acad Dermatol Venerol 2006 ; 21 : 219-26.
 
6) Jones-Caballero M, Pedrosa E, Penas PF. Self-reported adherence to treatment and quality of life in mild to moderate acne. Dermatology 2008 ; 217 : 309-14.
PubMed

V 治療

P.148 掲載の参考文献
1) 林伸和, 赤松浩彦, 岩月啓氏, ほか. 尋常性ざ瘡治療ガイドライン. 日皮会誌 2008 ; 118 : 1893-923.
 
P.155 掲載の参考文献
1) Thiboutot D, Gollnick H, Bettoli V, et al. New insight into the management of acne : an update from the global alliance to improve outcomes in acne group. J Am Acad Dermatol 2009 ; 60 : S1-50.
 
1) 林伸和, 赤松浩彦, 岩月啓氏, ほか. 尋常性ざ瘡治療ガイドライン. 日皮会誌 2008 ; 118 : 1893-923.
 
2) Gollnick H, Cunliff W, Berson D, et al. Management of acne : a report from a global alliance to improve outcomes in acne. J Am Acad Dermatol 2003 ; 49 : S1-37.
 
3) Thiboutot D, Gollnick H, Bettoli V, et al. New insight into the management of acne : an update from the global alliance to improve outcomes in acne group. J Am Acad Dermatol 2009 ; 60 : S1-50.
 
4) 川島眞, 赤松浩彦, 林伸和, ほか. 皮膚科専門医療機関におけるざ瘡患者実態調査. 臨皮 2008 ; 62 : 673-82.
 
5) Kawashima M, Harada S, Loesche C, et al. Adapalene 0.1% is effective and safe for Japanese patients with acne vulgaris : a randomized, multicenter, investigatorblinded, controlled study. J Dermatol Sci 2008 ; 49 : 241-8.
 
6) 川島眞, 原田昭太郎, Philippe Andres, ほか. One-year efficacy and safety of adapalene gel 0.1% gel in Japanese patients with acne vulgaris. 皮膚の科学 2007 ; 6 : 504-12.
 
7) Zhang JZ, Li LF, Tu YT, et al. A successful maintenance approach in inflammatory acne with adapalene gel 0.1% after an initial treatment in combination with clindamycin topical solution 0.1% or after monotherapy with clindamycin topical solution 1%. J Dermatol Treat 2004 ; 15 : 372-8.
 
P.161 掲載の参考文献
1) Koo J. How do you foster medication adherence for better acne vulgaris management. Skinmed 2003 ; 2 : 229-33.
 
1) 林伸和, 赤松浩彦, 岩月啓氏, ほか. 尋常性ざ瘡治療ガイドライン. 日皮会誌 2008 ; 118 : 1893-923.
 
2) 川島眞, 原田昭太郎, Philippe Andres, ほか. One-year efficacy and safety of adapalene gel 0.1% gel in Japanese patients with acne vulgaris. 皮膚の科学 2007 ; 6 : 504-12.
 
3) Wolf JE, Kaplan D, Kraus SJ, et al. Efficay and tolerability of combined topical treatment of acne vulgaris with adapalene and clindamycin : a multicenter, randomized, investigator-blinded study. J Am Acad Dermatol 2003 ; 49 : S211-7.
 
P.166 掲載の参考文献
1) 川島眞, 原田昭太郎, Philippe Andres, ほか. One-year efficacy and safety of adapalene gel 0.1% gel in Japanese patients with acne vulgaris. 皮膚の科学 2007 ; 6 : 504-12.
 
P.171 掲載の参考文献
1) Drake LA, Dinehart SM, Goltz RW, et al. Guidelines of care for chemical peeling. Guidelines/Outcomes Committee : American Academy of Dermatology. J Am Acad Dermatol 1995 ; 33 : 497-503.
PubMed
1) 梶田尚美, 伊東慶子, 若山実佳, ほか. 20%・40%グリコール酸ピーリングによる尋常性ざ瘡への臨床効果について. 皮膚臨床 2003 ; 45 : 1743-8. (エビデンスレベル III)
 
2) 古川福実, 松永佳世子, 上田説子, ほか. 日本皮膚科学会ケミカルピーリングガイドライン 2001. 日皮会誌 2001 ; 111 : 2081-5.
 
2) 林伸和, 川島眞. 尋常性ざ瘡に対する30%グリコール酸 (pH1.5) を用いたケミカルピーリングの有用性の検討. 臨皮 2003 ; 57 : 1213-6. (エビデンスレベル III)
 
3) 古川福実, 松永佳世子, 伊藤正俊, ほか. 日本皮膚科学会ケミカルピーリングガイドライン 2004. 日皮会誌 2004 ; 114 : 953-7.
 
3) 梶田尚美, 田中伸, 玉田康彦, ほか. 20%グリコール酸ピーリングの尋常性ざ瘡に対する治療効果について. 臨皮 2002 ; 56 : 883-5. (エビデンスレベル III)
 
4) 岸岡亜紀子, 山本有紀, 宮崎孝夫, ほか. ざ瘡に対するケミカルピーリングの臨床効果および有効性検討. Aesthet Dermatol 2004 ; 14 : 195-202. (エビデンスレベル III)
 
4) 古川福実, 松永佳世子, 秋田浩孝, ほか. 日本皮膚科学会ケミカルピーリングガイドライン (改訂第3版). 日皮会誌 2008 ; 118 : 347-55.
 
5) 米井希, 山本有紀, 上中智香子, ほか. 尋常性ざ瘡, 毛孔性苔癬, アトピー性皮膚炎の炎症後色素沈着に対するケイセイjorbiGAジェルの使用経験. Aesthet Dermatol 2002 ; 12 : 103-8. (エビデンスレベル IV)
 
5) 梶田尚美, 伊東慶子, 若山実佳, ほか. 20%・40%グリコール酸ピーリングによる尋常性ざ瘡への臨床効果について. 皮膚臨床 2003 ; 45 : 1743-8.
 
6) Hashimoto Y, Suga Y, Mizuno Y, et al. Salicylic acid peels in polyethylene glycol vehicle for the treatment of comedogenic acne in Japanese patients. Dermatol Surg 2008 ; 34 : 276-9. (エビデンスレベル III)
 
6) 林伸和, 川島眞. 尋常性ざ瘡に対する30%グリコール酸 (pH1.5) を用いたケミカルピーリングの有用性の検討. 臨皮 2003 ; 57 : 1213-6.
 
7) 岸岡亜紀子, 山本有紀, 古川福実, ほか. ざ瘡に対するケミカルピーリングの臨床効果および有効性検討. 日本美容皮膚科学会雑誌 2004 ; 14 : 195-202.
 
7) 大日輝記, 上田説子. サリチル酸マクロゴールピーリングによるざ瘡の治療効果. Aesthet Dermatol 2007 ; 17 : 59-67. (エビデンスレベル V)
 
8) 梶田尚美, 田中伸, 玉田康彦, ほか. 20%グリコール酸ピーリングの尋常性ざ瘡に対する治療効果について. 臨皮 2002 ; 56 : 883-5.
 
8) 梶田尚美. 20%サリチル酸によるケミカルピーリングについて. Aesthet Dermatol 2004 ; 14 : 55-8. (エビデンスレベル III)
 
9) Kessler E, Flanagan K, Chia C, et al. Comparison of alpha- and beta-hydroxy acid chemical peels in the treatment of mild to moderately severe facial acne vulgaris. Dermatol Surg 2008 ; 34 : 45-50.
PubMed
9) Lee HS, Kim IH. Salicylic acid peels for the treatment of acne vulgaris in Asian patients. Dermatol Surg 2003 ; 29 : 1196-9. (エビデンスレベル III)
 
10) Zander E. Treatment of acne vulgaris with salicylic acid pads. Clin Ther 1992 ; 14 : 247-53. (エビデンスレベル II)
 
10) Usuki A, Ohashi A, Funasaka Y, et al. The inhibitory effect of glycolic acid and lactid acid on melanin synthesis in melanoma cells. Exp Dermatol 2003 ; 12 (Suppl 2) : 43-50.
 
11) Yamamoto Y, Uede K, Furukawa F, et al. Effects of α-hydroxy acids on human skin of Japanese : the rationale for chemical peeling. J Dermatol 2006 ; 33 : 16-22.
 
11) Erbaci Z. Biweekly serial glycolic acid peels vs. long-term daily use of topical lowstrength glycolic acid in the treatment of atrophic acne scars. Int Dermatol 2000 ; 39 : 789-94. (エビデンスレベル II)
 
12) 北野幸恵, 内田日奈子. ざ瘡後陥凹瘢痕に対する高濃度部分的TCA法による治療経験. 形成外科 2006 ; 49 : 573-80. (エビデンスレベル V)
 
12) Tagami H, Tadaki T, Obata M, et al. Functional assessment of the stratum corneum under the influence of oral aromatic retinoid (etretinate) in guinea-pigs and humans. Comparison with topical retinoic acid treatment. Br J Dermatol 1992 ; 127 : 470-5.
PubMed
13) 長濱通子, 船坂陽子, 市橋正光. 日本人に適すると考えられたグリコール酸を用いたケミカルピーリング. 皮膚 2000 ; 42 : 503-8. (エビデンスレベル V)
 
14) 船坂陽子. グリコール酸による色素斑の治療. 臨皮2001 ; 55 (5 増) : 135-9. (エビデンスレベル V)
 
15) 宮本洋 : グリコール酸によるケミカルピーリングの経験. 日美外報 2002 ; 24 : 89-94. (エビデンスレベル V)
 
16) 薄木晶子, 船坂陽子, 倉田晴子, ほか. サリチル酸マクロゴールのrejuvenation効果-画像解析装置による検討. Aesthet Dermatol 2004 ; 14 : 40-6. (エビデンスレベル III)
 
17) Kligman D, Kligman AM. Salicylic acid peels for the treatment of photoaging. Dermatol Surg 1998 ; 24 : 325-8. (エビデンスレベル V)
 
18) Chun EY, Lee JB, Lee KH. Focal trichloroacetic acid peel method for benign pigmented lesions in dark-skinned patients. Dermatol Surg 2004 ; 30 : 512-6. (エビデンスレベル V)
 
19) Cotellessa C, Peris K, Onorati MT, et al. The use of chemical peelings in the treatment of different cutaneous hyperpigmentations. Dermatol Surg 1999 ; 25 : 450-4. (エビデンスレベル V)
 
20) Humphreys TR, Werth V, Dzubow L, et al. Treatment of photodamaged skin with trichloroacetic acid and topical tretinoin. J Am Acad Dermatol 1996 ; 34 : 638-44. (エビデンスレベル V)
 
21) Javaheri SM, Handa S, Kaur I, et al. Safety and efficacy of glycolic acid facial peel in Indian women with melasma. Int J Dermatol 2001 ; 40 : 354-7. (エビデンスレベル V)
 
22) Khunger N, Sarkar R, Jain RK. Tretinoin peels versus glycolic acid peels in the treatment of melasma in dark-skinned patients. Dermatol Surg 2004 ; 30 : 756-60. (エビデンスレベル III)
 
23) Coleman WP, Brody HJ. Efficacy of low-strength glycolic acid application in the treatment of melasma. Arch Dermatol 2003 ; 139 : 811. (エビデンスレベル VI)
 
24) Bari AU, Iqbal Z, Rahman SB. Tolerance and safety of superficial chemical peeling with salicylic acid in various facial dermatoses. Indian J Dermatol Venereol Leprol 2005 ; 71 : 87-90. (エビデンスレベル V)
 
25) Sharquie KE, Al-Tikreety MM, Al-Mashhadani SA. Lactic acid chemical peels as a new therapeutic modality in melasma in comparison to Jessner's solution chemical peels. Dermatol Surg 2006 ; 32 : 1429-36. (エビデンスレベル III)
 
26) Burns RL, Prevost-Blank PL, Lawry MA, et al. Glycolic acid peels for postinflammatory hyperpigmentation in black patients. A comparative study. Dermatol Surg 1997 ; 23 : 171-5. (エビデンスレベル III)
 
27) Funasaka Y, Sato H, Usuki A, et al. The efficacy of glycolic acid for treating wrinkles : analysis using newly developed facial imaging systems equipped with fluorescent illumination. J Dermatol Sci 2001 ; 27 (Suppl 1) : S53-9. (エビデンスレベル III)
 
P.177 掲載の参考文献
1) Stolar ME, Rossi GV, Barr M. The effect of various ointment bases on the percutaneous absorption of salicylates. I. Effect of type of ointment base. J Am Pharm Assoc Am Pharm Assoc 1960 ; 49 : 144-7.
PubMed
2) Imayama S, Ueda S, Isoda M. Histological changes in the skin of hairless mice following peeling with salicylic acid. Arch Dermatol 2000 ; 11 : 1390-5.
PubMed
3) Ueda S, Mitsugi K, Ichige K, et al. New formulation of chemical peeling agent : 30% salicylic acid in polyethylene glycol : absorption and distribution of 14C- salicylic acid in polyethylene glycol applied topically to skin of hairless mice. J Dermatol Sci 2002 ; 28 : 211-8.
PubMed
4) Dainichi T, Ueda S, Isoda M, et al. Chemical peeling with salicylic acid in polyethylene glycol vehicle suppresses skin tumour development in hairless mice. Br J Dermatol 2003 ; 148 : 906-12.
PubMed
5) Dainichi T, Ueda S, Furue M, et al. Chemical peeling by SA-PEG remodel photodamaged skin : suppressing p53 expression and normalizing kerarinocyte differentiation. J Invest Dermatol 2005 ; 126 : 416-21.
 
6) Dainichi T, Ueda S, Furue M, et al. By the grace of peeling : the brace function of the stratum corneum in the protection from photo-induced keratinocyte carcinogenesis. Arch Dermatol Res 2008 ; 300 (Suppl 1) : S31-8.
 
7) Dainichi T, Ueda S, Furue M, et al. Excellent clinical results with a new preparition for chemical peeling in acne : 30% salicylic acid in polyethylene glycol vehicle. Dermatol Surg 2008 ; 34 : 891-9.
PubMed
8) Hashimoto Y, Suga Y, Mizuno Y, et al. Salicylic acid peels in polyethylene glycol vehicle for the treatment of comedogenic acne in Japanese patients. Dermatol Surg 2008 ; 34 : 276-9.
PubMed
9) Isoda M, Ueda S, Imayama S. New formulation of chemical peeling agent. Histological evaluation in sun-damaged skin model in hairless mice. J Dermatol Sci 2001 ; 27 (Suppl 1) : s60-s67.
 
10) Dainichi T, Koga T, Furue M, et al. Paradoxical effect of trichloroacetic acid (TCA) on ultraviolet B-induced skin tumor formation. J Dermatol Sci 2003 ; 31 : 229-31.
PubMed
P.184 掲載の参考文献
1) Thiboutot D, Gollnick H, Bettoli V, et al. New insights into the management of acne : an update from the Global Alliance to Improve Outcomes in Acne group. J Am Acad Dermatol 2009 ; 60 : S1-50.
 
2) 林伸和, 赤松浩彦, 岩月啓氏, ほか. 尋常性ざ瘡治療ガイドライン. 日皮会誌 2008 ; 118 : 1893-923.
 
3) Plewig G, Holland KT, Nenoff P. Clinical and bacteriological evaluation of nadifloxacin 1% cream in patients with acne vulgaris : a double-blind, phase III study comparison study versus erythromycin 2% cream. Eur J Dermatol 2006 ; 16 : 48-55.
PubMed
4) Shalita A, Myers JA, Krochmal L, et al. The safety and efficacy of clindamycin phosphate foam 1% versus clindamycin phosphate topical gel 1% for the treatment of acne vulgaris. J Drugs Dermatol 2006 ; 4 : 48-56.
 
5) Kurokawa I, Akamatsu H, Nishijima S, et al. Clinical and bacteriologic evaluation of OPC-7251 in patients with acne : a double-blind group comparison study versus cream base. J Am Acad Dermatol 1991 ; 25 : 674-8.
 
6) Wolf JE, Kaplan D, Kraus SJ, et al. Efficacy and tolerability of combined topical treatment of acne vulgaris with adapalene and clindamycin : a multicenter, randomized, investigator-blinded study. J Am Acad Dermatol 2003 ; 49 (3 Suppl) : S211-7.
 
7) Leyden JJ, McGinley KJ, Cavalieri S, et al. Propionibacterium acnes resistance to antibiotics in acne patients. J Am Acad Dermatol 1983 ; 8 : 41-5.
PubMed
8) Ross JI, Snelling AM, Carnegie E, et al. Antibiotic-resistant acne : lessons from Europe. Br J Dermatol 2003 ; 148 : 467-78.
PubMed
9) Ishida N, Nakamura H, Noguchi N, et al. Antimicrobial susceptibilities of Propionibacterium acnes isolated from patients with acne vulgaris. Microbiol Immunol 2008 ; 52 : 621-4.
 
10) Langner A, Chu A, Goulden V, et al. A randomized, single-blind comparison of topical clindamycin + benzoyl peroxide and adapalene in the treatment of mild to moderate facial acne vulgaris. Br J Dermatol 2008 ; 158 : 122-9.
PubMed
11) Skoutelis AT, Lianou PE, Bassaris HP. In vivo potentiation of polymorphonuclear leukocyte chemotaxis by clindamycin. Infection 1993 ; 21 : 321-3.
PubMed
12) Sato E, Kato M, Kohno M, et al. Clindamycin phosphate scavenges hydroxyl radical. Int J Dermatol 2007 ; 46 : 1185-7.
PubMed
13) Oizumi N, Kawabata S, Hirao M, et al. Relationship between mutations in the DNA gyrase and topoisomerase IV genes and nadifloxacin resistance in clinically isolated quinolone-resistant Staphylococcus aureus. J Infect Chemother 2001 ; 7 : 191-4.
PubMed
14) Akamatsu H, Sasaki H, Kurokawa I, et al. Effect of nadifloxacin on neutrophil functions. J Int Med Res 1995 ; 23 : 19-26.
 
15) Kuwahara K, Kitazawa T, Kitagaki H, et al. Nadifloxacin, an antiacne quinolone antimicrobial, inhibits the production of proinflammatory cytokines by human peripheral blood mononuclear cells and normal human keratinocytes. J Dermatol Sci 2005 ; 38 : 47-55.
PubMed
16) Murata K, Sugita K, Kobayashi M, et al. Nadifloxacin downmodulates antigen-presenting functions of epidermal Langerhans cells and keratinocytes. J Dermatol Sci 2006 ; 42 : 91-9.
PubMed
17) Jain GK, Ahmed FJ. Adapalene pretreatment increases follicular penetration of clindamycin : in vitro and in vivo studies. Indian J Dermatol Venereol Leprol 2007 ; 73 : 326-9.
PubMed
P.189 掲載の参考文献
1) Garner SE, Eady EA, Popescu C, et al. Minocycline for acne vulgaris : efficacy and safety. Cochrane Database Syst Rev 2003 ; Issue 1 : CD002086.
 
2) Skidmore R, Kovach R, Walker C, et al. Effects of subantimicrobial-dose doxycycline in the treatment of moderate acne. Arch Dermatol 2003 ; 139 : 459-64.
PubMed
3) Plewig G, Petrozzi JW, Berendes U. Double blind study of doxycycline in acne vulgaris. Arch Dermatol 1970 ; 101 : 435-8.
PubMed
4) Harrison PV. A comparison of doxycycline and minocycline in the treatment of acne vulgaris. Clin Exp Dermatol 1988 ; 13 : 242-4.
PubMed
5) Ozolins M, Eady EA, Avery AJ, et al. Comparison of five antimicrobial regimens for treatment of mild to moderate inflammatory facial acne vulgaris in the community : randomized controlled trial. Lancet 2004 ; 364 : 2188-95.
PubMed
6) Katsambas A, Towarky AA, Stratigos J. Topical clindamycin phosphate compared with oral tetracycline in the treatment of acne vulgaris. Br J Dermatol 1987 ; 116 : 387-91.
PubMed
7) Gratton D, Raymond GP, Guertin-Larochelle S, et al. Topical clindamycin versus systemic tetracycline in the treatment of acne. J Am Acad Dermatol 1982 ; 7 : 50-3.
PubMed
8) Braathen LR. Topical clindamycin versus oral tetracycline and placebo in acne vulgaris. Scan J Infect Dis Suppl 1984 ; 43 : 71-5.
 
9) Burton J. A placebo-controlled study to evaluate the efficacy of topical tetracycline in the treatment of mild to moderate acne. Dermatology Research Group. J Int Med Res 1990 ; 18 : 94-103.
 
10) Blaney DJ, Cook CH. Topical use of tetracycline in the treatment of acne : a double-blind study comparing topical and oral tetracycline therapy and placebo. Arch Dermatol 1976 ; 112 : 971-3.
PubMed
11) Wong RC, Kang S, Heezen JL, et al. Oral ibupurofen and tetracycline for the treatment of acne vulgaris. J Am Acad Dermatol 1984 ; 11 : 1076-81.
PubMed
12) Gammon WR, Meyer C, Latis S, et al. Comparative efficacy of oral erythromycin versus oral tetracycline in the treatment of acne vulgaris. J Am Acad Dermatol 1986 ; 14 : 183-6.
 
13) Strauss JS, Krowchuk DP, Leyden JJ, et al. Guideline of care for acne vulgaris management. J Am Acad Dermatol 2007 ; 56 : 651-63.
PubMed
14) Ferahbas A, Utas S, Aykol D, et al. Clinical evaluation of roxithromycin : a doubleblind, placebo-controlled and crossover trial in patients with acne vulgaris. J Dermatol 2004 ; 31 : 6-9.
PubMed
15) 橋本明彦, 坪井廣美, 平松正浩, ほか. ざ瘡に対するroxithromycin (ルリッド) の有用性 : Minocyclineとの比較検討. 西日皮膚 1996 ; 58 : 135-7.
 
16) RXMざ瘡研究会. Roxithromycinの炎症性皮疹を伴う尋常性ざ瘡 (膿疱性ざ瘡) における臨床的検討. 西日皮膚 1997 ; 59 : 444-50.
 
17) 立花隆夫, 松吉徳久, 工藤比等志, ほか. ルリッドによる炎症性ざ瘡の治療. 皮膚科紀要 1993 ; 88 : 87-94.
 
18) 中村健一, 川名誠司, 原田晴美, ほか. ざ瘡に対するroxithromycin (ルリッド(R)) の有用性. 西日皮膚 1993 ; 6 : 1136-40.
 
19) 石川治, 宮地良樹, 工藤隆弘, ほか. クラリスロマイシン (クラリシッド錠) の炎症性ざ瘡に対する臨床的有用性の検討. 皮膚科紀要 1996 ; 91 : 403-7.
 
20) 坪井良治, 小池美佳, 瀧本玲子, ほか. 膿疱性ざ瘡に対するciprofloxacin錠の臨床的検討 : minocycline錠との比較. 化学療法の領域 1999 ; 15 : 909-16.
 
21) 早川律子. 丘疹・膿疱を主体とする尋常性ざ瘡に対するlomefloxacin (ロメバクト(R)) の臨床試験成績. 化学療法の領域 1992 ; 8 : 1380-7.
 
22) 松本忠彦. トシル酸トスフロキサシン錠の膿疱性ざ瘡, 嚢腫性ざ瘡および集簇性ざ瘡に対する臨床効果. 西日皮膚 1995 ; 57 : 375-8.
 
23) Kawada A, Aragane Y, Tezuka T. Levofloxacin is effective for inflammatory acne with high levels in the lesions : an open study. Dermatology 2002 ; 204 : 301-2.
PubMed
24) 高橋久, 大西誉光, 望月昭彦, ほか. 浅在性皮膚化膿性疾患に対するsparfloxacinの臨床的検討. 日化療誌 1991 ; 39 : 633-47.
 
25) 戸田憲一, 下中美香, 松島佐都子, ほか. 尋常性ざ瘡に対するファロペネムナトリウム (ファロム錠) の治療効果. 新薬と臨床 2006 ; 55 : 1439-45.
 
26) 遠藤英樹, 和田珠恵, 成田智彦, ほか. 炎症性皮疹をともなう尋常性ざ瘡に対するfaropenem (FRPM) の臨床研究-尋常性ざ瘡患者由来Propionibacterium acnesおよびStaphylococcus epidermidisに対する各種抗菌薬の抗菌活性. 化学療法の領域 2009 ; 25 : 479-86.
 
27) 林伸和. ざ瘡の抗菌薬内服療法 (ファロムの使用経験を含めて). Aesthetic Dermatol 2009 ; 19 : 223.
 
28) 早川律子, 松永佳世子, 鈴木真理, ほか. 経口抗製剤cefuroxime axetil (CXM-AX) の膿疱性ざ瘡に対する臨床試験成績. 皮膚 1989 ; 31 : 591-600.
 
29) Cunliffe WJ, Meynadier J, Alirezai M, et al. Is combined oral and topical therapy better than oral therapy alone in patients with moderate to moderately severe acne vulgaris? A comparison of the efficacy and safety of lymecycline plus adapalene gel 0.1%, versus lymecycline plus gel vehicle. J Am Acad Dermatol 2003 ; 49 : S218-26.
 
30) Thiboutot DM, Shalita AR, Yamauchi PS, et al. Combination therapy with adapalene gel 0.1% & doxycycline for severe acne vulgaris. Skinmed 2005 ; 4 : 138-46.
 
31) 乃木田俊辰. 炎症性皮疹を伴う尋常性ざ瘡に対するfaropenem内服とアダパレンゲル0.1%外用の併用療法の検討. 新薬と臨床 2010 ; 59 : 392-404.
 
32) 林伸和, 赤松浩彦, 岩月啓氏, ほか. 尋常性ざ瘡治療ガイドライン. 日皮会誌 2008 ; 118 : 1893-923.
 
33) Maddin WS, Landells ID, Poulin Y, et al. Treatment of acne vulgaris and prevention of acne scarring : Canadian consensus guidelines. J Cutan Med Surg 2000 ; 4 (Suppl 1) : S2-13.
 
P.194 掲載の参考文献
1) 小林裕美, 石井正光. 皮膚科における食事療法の現状. MB Derma 2003 ; 74 : 56-65.
 
2) 山本巖. 現在の漢方製剤の応用法を中心とした皮膚科臨床講座 IV : ざ瘡. The Kampo 1984 ; 2 : 282-7.
 
3) 高橋邦明. 皮膚疾患と和漢治療薬. 大塚恭男, 編. 臨床薬物治療学大系 20. 和漢医薬学. 東京 : 情報開発研究所 ; 1987. pp199-213.
 
4) 小林裕美. 皮膚科疾患. 水野修一, 編. 漢方内科学. 京都 : メディカルユーコン ; 2007. pp674-742.
 
5) 山本巖. 現在の漢方製剤の応用法を中心とした皮膚科臨床講座 6 : 湿疹・皮膚炎群 (1) 脂漏性皮膚炎. The Kampo 1986 ; 4 : 50-63.
 
6) 大熊守也. 尋常性ざ瘡の漢方内服・外用剤併用療法. 和漢医薬学会誌 1993 ; 10 : 131-4.
 
7) 高橋邦明. 皮膚疾患の漢方治療総論-中医学的理論を基礎として. 皮膚 1997 ; 39 : 1-23.
 
8) 小林裕美, 鶴田大輔, 水野信之, ほか. ニキビに対する漢方療法. 日臨皮会誌 2009 ; 26 : 475-80.
 
9) 小林裕美, 石井正光. 漢方を用いた治療のコツ. MB Derma 2010 ; 170 : 77-82.
 
10) 坂東正造. 病名漢方治療の実際-山本巖の漢方医学と構造主義. 京都 : メディカルユーコン ; 2002. pp360-94.
 
11) 橋本喜夫, 松尾忍, 飯塚一. ざ瘡に対する荊芥連翹湯の使用経験. 第12回皮膚科東洋医学研究会記録. 1994. pp46-53.
 
12) 小林裕美. 女性の皮膚疾患への漢方治療. 産婦人科の実際 2005 ; 54 : 1387-95.
 
13) 桑野重昭. 当帰芍薬散及び関連処方の作用と応用. 山本巖 (校閲). 医師・薬剤師のための漢方処方の基礎と臨床応用. 東京 : 廣川書店 ; 1997. pp61-89.
 
P.199 掲載の参考文献
1) Henderson BW, Dougherty TJ. How does photodynamic therapy work? Photochem Photobiol 1992 ; 55 : 145-57.
PubMed
2) Kennedy JC, Pottier RH, Pross DC. Photodynamic therapy with endogenous protoporphyrin : basic principles and present clinical experience. J Photochem Photobiol B 1990 ; 6 : 143-8.
PubMed
3) Divaris DX, Kennedy JC, Pottier RH. Phototoxic damage to sebaceous glands and hair follicles of mice after systemic administration of 5-aminolevulinic acid correlates with localized protoporphyrin IX fluorescence. Am J Phathol 1990 ; 136 : 891-7.
 
4) Hongcharu W, Taylor CR, Chang Y, et al. Topical ALA-photodynamic therapy for the treatment of acne vulgaris. J Invest Dermatol 2000 ; 115 : 183-92.
PubMed
5) Itoh Y, Ninomiya Y, Tajima S, et al. Photodynamic therapy for acne vulgaris with topical 5-aminolevulinic acid. Arch Dermatol 2000 ; 136 : 1093-5.
PubMed
6) Itoh Y, Ninomiya Y, Tajima S, et al. Photodynamic therapy of acne vulgaris with topical δ-aminolaevulinic acid and incoherent light in Japanese patients. Br J Dermatol 2001 ; 144 : 575-9.
 
7) 林伸和, 赤松浩彦, 岩月啓氏, ほか. 尋常性ざ瘡治療ガイドライン. 日皮会誌 2008 ; 118 : 1893-923.
 
8) Melo TB, Johnsson M. In vivo porphyrin fluorescence for Propionibacterium acnes. Dermatologica 1982 ; 164 : 167-74.
PubMed
9) Peng Q, Warloe T, Berg K, et al. 5-Aminolevulinic acid-based photodynamic therapy. Clinical research and future challenges. Cancer 1997 ; 79 : 2282-308.
PubMed
10) Konig K, Schneckenburger H, Ruck A, et al. In vivo photoproduct formation during PDT with ALA-induced endogenous porphyrins. J Photochem Photobiol B 1993 ; 18 : 287-90.
PubMed
11) Burton JL, Cunliffe WJ, Stafford I, et al. The prevalence of acne vulgaris in adolescence. Br J Dermatol 1971 ; 85 : 119-26.
PubMed
12) 下田貴子, 坪内利江子, 川名誠司. 尋常性ざ瘡に対する外用ALA-PDTの効果と副反応の検討. 日皮会誌 2008 ; 118 : 403-7.
 
13) Kimura M, Itoh Y, Yokuya Y, et al. Delta aminolevulinic acid-based photodynamic therapy for acne on the body. J Dermatol 2004 ; 31 : 956-60.
 
14) 伊藤嘉恭. ニキビの治療. Aesthet Dermatol 2005 ; 15 : 15-21.
 
15) 立原利江子. ざ瘡のモデルマウスにおけるALAのkinetics. Aesthet Dermatol 2005 ; 15 : 9-14.
 
16) Kosaka S, Miyoshi N, Akilov OE, et al. Targeting of sebaceous glands by δ-aminolevulinic acid-based photodynamic therapy : an in vivo study. Lasers Surg Med 2011 ; 43 : 376-81.
 
P.206 掲載の参考文献
1) Cunliffe WJ, Goulden V. Phototherapy and acne vulgaris. Br J Dermatol 2000 ; 142 : 855-6.
PubMed
2) Hongcharu W, Taylor CR, Chang Y, et al. Topical ALA-photodynamic therapy for the treatment of acne vulgaris. J Invest Dermatol 2000 ; 115 : 183-92.
PubMed
3) Wei-Li SL, Shalita AR, Poh-Fitzpatrick MB. Comparative studies of porphyrin production in Propionibacterium acnes and Propionibacterium granulosum. J Bacter 1978 ; 133 : 811-5.
 
4) Arakane K, Ryu A, Hayashi C, et al. Singlet oxygen generation from coproporphyrin in Propionibacterium acnes on irradiation. Biochem Biophys Res Commun 1996 ; 223 : 578-82.
PubMed
5) Ashkenazi H, Malik Z, Harth Y, et al. Eradication of Propionibacterium acnes by its endogenic porphyrins after illumination with high intensity blue light. FEMS Immunol Med Microbiol 2003 ; 35 : 17-24.
PubMed
6) Schnitkind E, Yaping E, Geen S, et al. Antiinflammatory properties of narrow band blue light. J Drugs Dermatol 2006 ; 5 : 605-10.
 
7) Thiboutot D, Gollnick H, Bettoli V, et al. New insights into the management of acne : an update from the Global Alliance to Improve Outcomes in Acne group. J Am Acad Dermatol 2009 ; 60 (5 Suppl) : S1-50.
 
8) Tzung T-Y, Wu K-H, Huang M-L. Blue light phototherapy in the treatment of acne. Photoderm Photoimmunol Photomed 2004 ; 20 : 266-9.
 
9) Papageorgiou P, Katsambas A, Chu A. Phototherapy with blue (415 nm) and red (660 nm) light in the treatment of acne vulgaris. Br J Dermatol 2000 ; 142 : 973-8.
PubMed
10) Morton CA, Scholefield RD, Whitehurst C, et al. An open study to determine the efficacy of blue light in the treatment of mild to moderate acne. J Dermatolog Treat 2005 ; 16 : 219-23.
PubMed
11) Omi T, Bjerring P, Sato S, et al. 420 nm intense continuous light therapy for acne. J Cosmet Laser Ther 2004 ; 6 : 156-62.
PubMed
12) Kawada A, Aragane Y, Kameyama H, et al. Acne phototherapy with a high-intensity, enhanced, narrow-band, blue light source : an open study and in vitro investigation. J Derm Sci 2002 ; 30 : 129-35.
 
13) Noborio R, Nishida E, Kurokawa M, et al. A new targeted blue light phototherapy for the treatment of acne. Photodermatol Photoimmunol Photomed 2007 ; 23 : 32-4.
PubMed
14) Elman M, Lebzelter J. Light therapy in the tratement of acne vulgaris. Derm Surg 2004 ; 30 : 140-6.
 
15) Na JI, Suh DH. Red light phototherapy alone is effective for acne vulgaris : randomized, single-blinded clinical trial. Dermatol Surg 2007 ; 33 : 1228-33.
PubMed
16) Zane C, Capezzera R, Pedretti A, et al. Non-invasive diagnostic evaluation of phototherapeutic effects of red light phototherapy of acne vulgaris. Photodermatol Photoimmunol Photomed 2008 ; 24 : 244-8.
PubMed
17) Goldberg DJ, Russell BA. Combination blue (415 nm) and red (633 nm) LED phototherapy in the treatment of mild to severe acne vulgaris. J Cosmet Laser Ther 2006 ; 8 : 71-5.
PubMed
18) Lee SY, You CE, Park MY. Blue and red light combination LED phototherapy for acne vulgaris in patients with skin phototype IV. Lasers Surg Med 2007 ; 39 : 180-8.
PubMed
19) Sadick NS. Handheld LED array device in the treatment of acne vulgaris. J Drugs Dermatol 2008 ; 7 : 347-50.
PubMed
P.211 掲載の参考文献
1) 林伸和, 赤松浩彦, 岩月啓氏, ほか. 尋常性ざ瘡治療ガイドライン. 日皮会誌 2008 ; 118 : 1893-923.
 
2) Kienle A, Hibst R. A new optimal wavelength for treatment of port wine stains? Phys Med Biol 1995 ; 40 : 1559-76.
PubMed
3) Kono T, Groff WF, Sakurai H. Pulsed dye laser treatment of port wine stains. Ann Plast Surg 2006 ; 56 : 460-3.
PubMed
4) Kono T, Sakurai H, Takeuchi M, et al. Evaluation of fluence and pulse-duration on purpuric threshold using a variable-pulse pulsed-dye laser in the treatment of port wine stains. J Dermatol 2006 ; 33 : 471-4.
 
5) Kono T, Sakurai H, Groff WF, et al. Comparison study of a traditional pulsed dye laser versus a long-pulsed dye laser in the treatment of early childhood hemangiomas. Laser Surg Med 2006 ; 38 : 112-5.
PubMed
6) Kono T, Yamaki T, Ercocen A, et al. Treatment of leg vein with variable-pulse high-fluence pulsed-dye laser. Laser Surg Med 2004 ; 35 : 62-7.
 
7) Kono T, Ercocen A, Nakazawa H, et al. Treatment of hypertrophic scars using a long-pulsed dye laser with cryogen-spray cooling. Ann Plast Surg 2005 ; 54 : 487-93.
PubMed
8) Kono T, Chan H, Groff WF, et al. Comparison study of intense pulsed light versus a long-pulse pulsed dye laser in the treatment of facial skin rejuvenation. Ann Plast Surg 2007 ; 59 : 479-83.
 
9) Kono T, Chan H, Groff WF, et al. Long-pulse pulsed dye laser delivered with compression for treatment of facial lentigines. Dermatol Surg 2007 ; 33 : 945-50.
PubMed
10) Kono T, Chan H, Anderson RR, et al. Q-switched ruby vs. long-pulsed dye laser delivered with compression for treatment of facial lentigines in Asians. Laser Surg Med 2006 ; 38 : 94-7.
 
11) 河野太郎, 野崎幹弘. 日常診療における美容皮膚科・美容皮膚外科のコツ-私はこうしている : 色素レーザー, Vビームを中心に. MB Derma 2006 ; 118 : 122-6.
 
12) Seaton ED, Mouser PE, Charakida A, et al. Investigation of the mechanism of action of nonablative pulsed-dye laser therapy in photorejuvenation and inflammatory acne vulgaris. Br J Dermatol 2006 ; 155 : 748-55.
PubMed
13) Orringer JS, Kang S, Hamilton T, et al. Treatment of acne vulgaris with a pulsed dye laser : a randomized controlled trial. JAMA 2004 ; 16 : 291 : 2834-9.
PubMed
14) Alexiades-Armenakas M. Long-pulsed dye laser-mediated photodynamic therapy combined with topical therapy for mild to severe comedonal, inflammatory, or cystic acne. J Drugs Dermatol 2006 ; 5 : 45-55.
PubMed
15) Leheta TM. Role of the 585-nm pulsed dye laser in the treatment of acne in comparison with other topical therapeutic modalities. J Cosmet Laser Ther 2009 ; 11 : 118-24.
PubMed
16) Choi YS, Suh HS, Yoon MY, et al. Intense pulsed light vs. pulsed-dye laser in the treatment of facial acne : a randomized split-face trial. J Eur Acad Dermatol Venereol 2010 ; 24 : 773-80.
 
17) Yoon HJ, Lee DH, Kim SO, et al. Acne erythema improvement by long-pulsed 595-nm pulsed-dye laser treatment : a pilot study. J Dermatolog Treat 2008 ; 19 : 38-44.
 
18) Harto A, Garcia-Morales I, Beldar P, et al. Pulsed dye laser treatment of acne. Study of clinical and mechanism of action. Actas Dermosifiliogr 2007 ; 98 : 415-9.
 
19) Rohrer TE, Chatrath V, Iyengar V. Does pulse stacking improve the results of treatment with variable-pulse pulsed-dye lasers? Dermatol Surg 2004 ; 30 : 163-7.
PubMed
P.216 掲載の参考文献
1) Jacob CI, Dover JS, Kaminer MS. Acne scarring : a classification system and review of treatment options. J Am Acad Dermatol 2001 ; 45 : 109-17.
PubMed
2) Goodman GJ. Post-acne scarring : a short review of its pathophysiology. Australas J Dermatol 2001 ; 42 : 84-90.
 
3) Cotterill JA, Cunliffe WJ. Suicide in dermatological patients. Br J Dermatol 1997 ; 137 : 246-50.
PubMed
4) Goodman GJ, Baron JA. The management of postacne scarring. Dermatol Surg 2007 ; 33 : 1175-88.
PubMed
5) Khunger N. Standard guidelines of care for acne surgery. Indian J Dermatol Venereol Leprol 2008 ; 74 : S28-36.
PubMed
6) Rivera AE. Acne scarring : a review and current treatment modalities. J Am Acad Dermatol 2008 ; 59 : 659-76.
PubMed
7) Dainichi T, Ueda S, Fumimori T, et al. Skin tightening effect using fractional laser treatment II : a pilot animal study on skin remodeling. Dermatol Surg 2010 ; 36 : 71-5.
 
8) Dainichi T, Kawaguchi A, Ueda S, et al. Skin tightening effect using fractional laser treatment : I. a randomized half-side pilot study on faces of patients with acne. Dermatol Surg 2010 ; 36 : 66-70.
 
9) AlGhamdi KM. A better way to hold a Nokor needle during subcision. Dermatol Surg 2008 ; 34 : 378-9.
 
10) Burres SA. Recollagenation of acne scars. Dermatol Surg 1996 ; 22 : 364-7.
PubMed
11) Manstein D, Herron GS, Sink RK, et al. Fractional photothermolysis : a new concept for cutaneous remodeling using microscopic patterns of thermal injury. Lasers Surg Med 2004 ; 34 : 426-38.
PubMed
12) 須賀康. フラクショナルレーザー療法の実際 : その基礎と応用について. 日レ医誌 2010 ; 31 : 65-71.
 
13) 春名邦隆, 須賀康. 瘢痕治療のコツ-陥凹性瘢痕に対する治療. MB Derma 2010 ; 170 : 55-61.
 
14) Lee DH, Choi YS, Min SU, et al. Comparison of a 585-nm pulsed dye laser and a 1064-nm Nd : YAG laser for the treatment of acne scars : a randomized split-face clinical study. J Am Acad Dermatol 2009 ; 60 : 801-7.
 
15) 古川福実, 松永佳世子, 秋田浩孝, ほか. 日本皮膚科学会ケミカルピーリングガイドライン (改訂第3版). 日皮会誌 2008 ; 118 : 347-55.
 
16) Kang S, Cho S, Chung JH, et al. Inflammation and extracellular matrix degradation mediated by activated transcription factors nuclear factor-B and activator protein-1 in inflammatory acne lesions in vivo. Am J Pathol 2005 ; 166 : 1691-9.
 
17) Jalian HR, Liu PT, Kanchanapoomi M, et al. All-trans retinoic acid shifts Propionibacterium acnes-induced matrix degradation expression profile toward matrix preservation in human monocytes. J Invest Dermatol 2008 ; 128 : 2777-82.
PubMed
18) Zouboulis CC. Cryosurgery in dermatology. Eur J Dermatol 1998 ; 8 : 466-74.
PubMed
P.221 掲載の参考文献
1) Fitzpatrick RE, Goldman MP, Satur NM, et al. Pulsed carbon dioxide laser resurfacing of photoaged facial skin. Arch Dermatol 1996 ; 132 : 395-402.
PubMed
2) Nanni CA, Alster TS. Complications of carbon dioxide laser resurfacing. An evaluation of 500 patients. Dermatol Surg 1998 ; 24 : 315-20.
PubMed
3) Manstein D, Herron GS, Sink RK, et al. Fractional photothermolysis : a new concept for cutaneous remodeling using microscopic patterns of thermal injury. Lasers Surg Med 2004 ; 34 : 426-38.
PubMed
4) 河野太郎, 野崎幹弘. Fractional Laser によるSkin Rejuvenation. 日形会誌 2005 ; 25 : 421-4.
 
5) 河野太郎, 野崎幹弘. フラクセルレーザーによるskin rejuvenation. MB Derma 2006 ; 118 (増刊号) : 153-6.
 
6) Ross RB, Spencer J. Scarring and persistent erythema after fractionated ablative CO2 laser resurfacing. J Drugs Dermatol 2008 ; 7 : 1072-3.
PubMed
7) Fife DJ, Fitzpatrick RE, Zachary CB. Complications of fractional CO2 laser resurfacing : four cases. Lasers Surg Med 2009 ; 41 : 179-84.
PubMed
8) Avram MM, Tope WD, Yu T, et al. Hypertrophic scarring of the neck following ablative fractional carbon dioxide laser resurfacing. Lasers Surg Med 2009 ; 41 : 185-8.
PubMed
9) 長谷川敏男, 松倉知之, 須賀康, ほか. Fractional photothermolysisを用いたエルビウムグラスレーザーによるskin textureの改善. 日レ会誌 2006 ; 27 : 24-9.
 
10) Kono T, Chan HH, Groff WF, et al. Prospective direct comparison study of fractional resurfacing using different fluences and densities for skin rejuvenation in Asians. Lasers Surg Med 2007 ; 39 : 311-4.
PubMed
11) Chan HH, Manstein D, Yu CS, et al. The prevalence and risk factors of post-inflammatory hyperpigmentation after fractional resurfacing in Asians. Lasers Surg Med 2007 ; 39 : 381-5.
PubMed
12) 河野太郎, 野崎幹弘. 眼瞼若返りのためのレーザーおよびプラズマ治療. 形成外科 2008 ; 51 : 911-6.
 
13) 須賀康. フラクショナルレーザー療法の実際. 日レ会誌 2010 ; 31 : 65-71.
 
14) 青木律. フラクショナルレーザーの上手な使い方. 形成外科 2009 ; 52 : 289-95.
 
15) 河野太郎, 櫻井裕之. 瘢痕に対するプラズマ治療とフラクショナルレーザー治療. Scar Manage 2010 ; 4 : 10-4.
 
16) Metelitsa AI, Alster TS. Fractionated laser skin resurfacing treatment complications : a review. Dermatol Surg 2010 ; 36 : 299-306.
PubMed
P.226 掲載の参考文献
1) 宮崎孝夫. にきび瘢痕の治療. 宮地良樹, 編. 皮膚科診療最前線シリーズ. にきび最前線. 大阪 : メディカルレビュー社 ; 2006 ; pp168-71.
 
2) 宮崎孝夫. ざ瘡瘢痕. 大原國章, ほか編. 皮膚科診療プラクティス 4. Day Surgeryの実際. 東京 : 文光堂 ; 1998. pp259-61.
 
3) 宮崎孝夫. ニキビの瘢痕治療. 古川福実, 編. 皮膚科診療プラクティス 18. ニキビ治療の技法. 東京 : 文光堂 ; 2005. pp171-5.
 
4) 宮崎孝夫. にきび. 松永佳世子, 編. 皮膚科診療プラクティス 11. ケミカルピーリングとコラーゲン注入のすべて : 美容皮膚科最前線. 東京 : 文光堂 ; 2001. pp107-11.
 
5) 宮崎孝夫. 私の治療経験 (ピーリングのコツ). Aesthetic Dermatology 2002 ; 12 : 19-21.
 
6) 宮崎孝夫. ざ瘡・ざ瘡瘢痕の治療 (1) ケミカルピーリング. MB Derma 2002 ; 67 : 71-6.
 
7) 宮崎孝夫. ざ瘡瘢痕. Visual Dermatology 2008 ; 7 : 1234-5.
 
8) 鄭憲. トリクロロ酢酸 (TCA) によるfacial chemical peeling. Aesthetic Dermatology 1998 ; 8 : 21.
 
9) Brody HJ. Chemical Peeling and Resurfacing. St. Louis ; Mosby-Year Book ; 1992.
 
10) Yonei N, Kanazawa N, Ohtani T, et al. Induction of PDGF-B in TCA-treated epidermal keratinocytes. Arch Dermatol Res 2007 ; 299 : 433-40.
PubMed
11) 宮崎孝夫. TCAによるケミカルピーリング施術. MB Derma 2005 ; 106 : 66-72.
 
12) 宮崎孝夫. ざ瘡瘢痕. 古川福実, ほか編. ケミカルピーリング これが私のコツと技. 東京 : 南山堂 ; 2009. pp149-54.
 
P.232 掲載の参考文献
1) Koutun W, Lucky AW, Niknaian M, et al. Efficacy and safety of 3 mg drospirenone/20 mcg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris : randomized, double-blind, placebo-controlled trial. Contraception 2008 ; 77 : 249-56.
 
1) 日本産科婦人科学会, 編. 低用量経口避妊薬の使用に関するガイドライン (改訂版). 2005.
 
2) 相澤浩, 新村眞人. 女性ざ瘡患者の血中アンドロゲン動態 : ロ. リンデロール投与の影響. ホと臨床 1996 ; 44 : 531-5.
 
3) 松本安代, 山辺晋吾, 浅原彩子. 低用量ピルによるニキビ治療の効果. 産と婦 2008 ; 75 : 640-5.
Medical*Online
4) 松本安代, 山辺晋吾, 村上雄太ほか. 低用量ピルの種類による満足度と使用感について. 産婦治療 2009 ; 99 : 96-101.
 
5) Dickey RP. Biological actibity of oral contraceptive components. In : Managing Contraceptive Pill Patients. 8th ed. Fort Collins : EMIS Medical Publishers ; 1994. p130.
 
P.238 掲載の参考文献
1) 朝田康夫. 尋常性ざ瘡-尋常性ざ瘡の重症度規定. にきび (尋常性ざ瘡). 東京 : 金原出版 ; 1983. pp60-2.
 
2) Parish LC, Witkowski JA. The enigma of acne therapy : the acne abscess. Am J Med Sci 1967 ; 254 : 769-76.
PubMed
3) Levine RM, Rasmussen JE. Intralesional corticosteroids in the treatment of nodulocystic acne. Arch Dermatol 1983 ; 119 : 480-1.
PubMed
4) 林伸和, 赤松浩彦, 岩月啓氏, ほか. 尋常性ざ瘡治療ガイドライン. 日皮会誌 2008 ; 118 : 1893-923.
 
5) 西嶋攝子, 黒川一郎, 和泉 宏, ほか. 慢性侵蝕性膿瘍性膿皮症 (加藤) を主病像とした全身広汎性慢性膿皮症の1例. 臨皮1985 ; 39 : 705-9.
 
6) 宮地良樹, 吉岡晃, 尾口基. 集簇性ざ瘡に対するDDS療法その作用機序の検討. 皮膚科紀要 1985 ; 80 : 277-81.
 
7) Kligman AM. How to use topical tretinoin in treating acne. Cutis 1995 ; 56 : 83-4.
PubMed
8) Karvonen SL, Rasanen L, Cunliffe WJ, et al. Delayed hypersensitivity to Propionibacterium acnes in patients with severe nodular acne and acne fulminans. Dermatology 1994 ; 189 : 344-9.
PubMed
9) Honma M, Murakami M, Iinuma S, et al. Acne fulminans following measles infection. J Dermatol 2009 ; 36 : 471-3.
PubMed
P.243 掲載の参考文献
1) 林伸和, 赤松浩彦, 岩月啓氏, ほか. 尋常性ざ瘡治療ガイドライン. 日皮会誌 2008 ; 118 : 1893-923.
 
1) Danby FW. Nutrition and acne. Clin Dermatol 2010 ; 28 : 598-604.
PubMed
2) Bourne S, Jacobs A. Observations on acne, seborrhea, and obesity. Br Med J 1956 ; 1 : 1268-70.
PubMed
3) Wolf R, Matz H, Orion E. Acne and diet. Clin Dermatol 2004 ; 22 : 387-93.
PubMed
4) Cordain L, Lindeberg S, Hurtado M, et al. Acne vulgaris : a disease of Western civilization. Arch Dermatol 2002 ; 138 : 1584-90.
PubMed
5) Schaefer O. When the Eskimo comes to town. Nutr Today 1971 ; 6 : 8-16.
 
6) Verhagen A, Koten J, Chaddah V, et al. Skin diseases in Kenya. A clinical and histopathological study of 3,168 patients. Arch Dermatol 1968 ; 98 : 577-86.
 
7) Ratnam A, Jayaraju K. Skin disease in Zambia. Br J Dermatol 1979 ; 101 : 449-53.
PubMed
8) Park R. The age distribution of common skin disorder in the Bantu of Pretoria, Transvaal. Br J Dermatol 1968 ; 80 : 758-61.
PubMed
9) Frisch R, Wyshak G, Vicent L. Delayed menarche and amenorrhea in ballet dancers. N Engl J Med 1980 ; 303 : 17-9.
 
10) Frisch R. Weight at menarche : similarity for well-nourished and undernourished girls at differing ages, and evidence for historical constancy. Pediatrics 1972 ; 50 : 445-50.
PubMed
11) Lucky AW, Biro FM, Huster GA, et al. Acne vulgaris in premenarcheal girls. Arch Dermatol 1994 ; 130 : 308-14.
PubMed
12) Ludwig DS. The glycemic index : physiological mechanism relating to obesity, diabetes, and cardiovascular disease. JAMA 2002 ; 8 : 2414-23.
 
13) Adebamowo CA, Spiegelman D, Danby FW, et al. High school dietary dairy intake and teenage acne. J Am Acad Dermatol 2005 ; 52 : 207-14.
PubMed
14) Adebamowo CA, Spiegelman D, Berekey CS, et al. Milk consumption and acne in adolescent girls. Dermatol Online J 2006 ; 12 : 1.
 
15) Danby FW. Acne and milk, the diet myth, and beyond. J Am Acad Dermatol 2005 ; 52 : 360-2.
PubMed
16) Pennington JAT. Iodine concentrations in US milk : variation due to time, season, and region. J Dairy Sci 1990 ; 73 : 3421-7.
 
17) Smith RN, Braue A, Varigos GA, et al. The effect of a low glycemic load diet on acne vulgaris and the fatty acid composition of skin surface triglycerides. J Dermatol Sci 2008 ; 50 : 41-52.
PubMed
18) Simopoulos AP. Omega-3 fatty acids in inflammation and autoimmune diseases. J Am Coll Nutr 2002 ; 21 : 495-505.
PubMed
19) James MJ, Gibson RA, Cleland LG. Dietary polyunsaturated fatty acids and inflammatory mediator production. Am J Clin Nutr 2000 ; 71 : S343-8.
 
20) Mayer K, Meyer S, Reinholz-Muhly M, et al. Short-time infusion of fish oil-based lipid emulsions, approved for parenteral nutrition, reduces monocyte pro-inflammatory cytokine generation and adhesive interaction with endothelium in humans. J Immunol 2003 ; 171 : 4837-43.
 
21) Zhao Y, Joshi-Barve S, Barve S, et al. Eicosapentaenoic acid prevents LPS- induced TNF-alpha expression by preventing NF-kappaB activation. J Am Coll Nutr 2004 ; 23 : 71-8.
PubMed
22) Michaelsson G, Juhlin L, Vahlquist A. Effects of oral zinc and vitamin A in acne. Arch Dermatol 1977 ; 113 : 312-36.
 
23) Van Vloten WA, Bos LP. Skin lesions in acquired zinc deficiency due to parenteral nutrition. Dermatologica 1978 ; 156 : 175-83.
PubMed
24) Fulton JE Jr, Plewig G, Kligman AM. Effect of chocolate on acne vulgaris. JAMA 1969 ; 210 : 2071-4.
PubMed
25) Bett DG, Morland J, Yudkin J. Sugar consumptionin acne vulgaris and seborrhoeic dermatitis. Br Med J 1967 ; 3 : 153-5.
 
P.248 掲載の参考文献
1) 窪田泰夫, 松岡由恵, 中井浩三, ほか. 成人女性ざ瘡患者を対象としたスキンケア製品の使用経験と皮膚生理機能および患者QOLに及ぼす影響. 西日皮膚 2008 ; 70 : 429-35.
 
2) 川島眞, 根本治, 森川玲子, ほか. 尋常性ざ瘡を対象としたクレンジングオイルの使用試験. 臨皮 2007 ; 61 : 654-9.
 
3) 大江昌彦, 白髭由恵, 窪田泰夫, ほか. ざ瘡寛解期における化粧指導とスキンケア製品によるProactive Managementの有用性. 日本化粧品技術者会誌 2010 ; 44 : 127-32.
 
4) 林伸和, 赤松浩彦, 岩月啓氏, ほか. 尋常性ざ瘡治療ガイドライン. 日皮会誌 2008 ; 118 : 1893-923.
 
5) Kubota Y, Shirahige Y, Nakai K, et al. Community-based epidemiological study of psychosocial effects of acne in Japanese adolescents. J Dermatol 2010 ; 37 : 617-22.
PubMed
6) Yamamoto A, Takenouchi K, Ito M. Impaired water barrier function in acne vulgaris. Arch Dermatol Res 1995 ; 287 : 214-8.
PubMed
7) 上田由紀子. ニキビが治るまでのヘアスタイル. 上田由紀子, ほか編. 皮膚科外来診療スーパーガイド. 東京 : 中山書店 ; 2010. pp190-1.
 
P.255 掲載の参考文献
1) Hayashi N, Imori M, Yanagisawa M, et al. Make-up improves the quality of life of acne patients without aggravating acne eruptions during treatments. Eur J Dermatol 2005 ; 15 : 284-7.
PubMed
2) Matsuoka Y, Nakai K, Yoneda K, et al. Effects of skin care and makeup under instructions from dermatologists on the quality of life of female patients with acne vulgaris. J Dermatol 2006 ; 33 : 745-52.
 
3) 田崎美弥子, 中根允文. 世界保健機構・精神保健と薬物乱用予防部, 編. WHO QOL26手引. 東京 : 金子書房 ; 1997.
 
4) 福原俊一, 編. 皮膚疾患のQOL評価. DLQI, Skindex 29 日本語版マニュアル. 東京 : 照林社 ; 2004.
 
5) Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) -a simple practical measure for routine clinical use. Clin Exp Dermatol 1994 ; 19 : 210-6.
 
P.261 掲載の参考文献
1) 小林美咲. ざ瘡. Visual Dermatology 2005 ; 4 : 478-9.
 
2) Fried RG, Wechsler A. Psychological problems in the acne patient. Dermatol Ther 2006 ; 19 : 237-40.
 
3) Baldwin HE. The interaction between acne vulgaris and psyche. Cutis 2002 ; 70 : 133-9.
PubMed
4) Feldman W, Hodgson C, Corber S, et al. Health concerns and health-related behaviours of adolescents. CMAJ 1986 ; 134 : 489-93.
PubMed
5) Uhlenhake E, Yentzer BA, Feldman SR. Acne vulgaris and depression. J Cosmet Derm 2010 ; 9 : 59-63.
 
6) Kellet SG, Gawkrodger DJ. The psychosocial and emotional impact of acne and the effect of treatment with isotretinoin. Br J Dermatol 1999 ; 140 : 273-82.
 
7) Jones-Caballero M, Pedrosa E, Penas PF. Self-reported adherence to treatment and quality of life in mild to moderate acne. Dermatology 2008 ; 217 : 309-14.
PubMed
P.266 掲載の参考文献
1) 渡辺晋一, 訳. 尋常性ざ瘡 (ニキビ) の治療. JAMA (日本語版) 2005 ; 26 : 77-88.
 
2) Gollnick H, Cunliffe WJ, Berson D, et al. Management of acne : a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol 2003 ; 49 (1 suppl) : S1-37.
 

VI 臨床経過・予後

P.274 掲載の参考文献
1) Cooper AJ. Systematic review of Propionibacterium acnes resistance to systemic antibiotics. Med J Aust 1998 ; 169 : 259-61.
PubMed
2) Coates P, Vyakrnam S, Eady EA, et al. Prevalence of antibiotic-resistant propionibacteria on the skin of acne patients : 10-year surveillance data and snapshot distribution study. Br J Dermatol 2002 ; 146 : 840-8.
PubMed
3) Jackson JM, Fu JJ, Almekinder JL. A randomized, investigator-blinded trial to assess the antimicrobial efficacy of a benzoyl peroxide 5%/clindamycin phosphate 1% gel compared with a clindamycin phosphate 1.2%/tretinoin 0.025% gel in the topical treatment of acne vulgaris. J Drugs Dermatol 2010 ; 9 : 131-6.
 
4) Dumont-Wallon G, Moyse D, Blouin E, et al. Bacterial resistance in French acne patients. Int J Dermatol 2010 ; 49 : 283-8.
PubMed
5) Ross JI, Snelling AM, Carnegie E, et al. Antibiotic-resistant acne : lessons from Europe. Br J Dermatol 2003 ; 148 : 467-78.
PubMed
6) Gonzalez R, Welsh O, Ocampo J, et al. In vitro antimicrobial susceptibility of Propionibacterium acnes isolated from acne patients in northern Mexico. Int J Dermatol 2010 ; 49 : 1003-7.
PubMed
7) Tan HH, Tan AW, Barkham T, et al. Community-based study of acne vulgaris in adolescents in Singapore. Br J Dermatol 2007 ; 157 : 547-51.
PubMed
8) Oprica C, Emtestam L, Hagstromer L, et al. Clinical and microbiological comparisons of isotretinoin vs. tetracycline in acne vulgaris. Acta Derm Venereol 2007 ; 87 : 246-54.
PubMed
9) Ergin C, Ergin S, Kaleli I, et al. Nasal antibiotic-resistant Propionibacterium acnes carriage in acne vulgaris patients in Turkey. J Dermatol 2006 ; 33 : 899-901.
 
10) Plewig G, Holland KT, Nenoff P. Clinical and bacteriological evaluation of nadifloxacin 1% cream in patients with acne vulgaris : a double-blind, phase III comparison study versus erythromycin 2% cream. Eur J Dermatol 2006 ; 16 : 48-55.
PubMed
11) Ishida N, Nakaminami H, Noguchi N, et al. Antimicrobial susceptibilities of Propionibacterium acnes isolated from patients with acne vulgaris. Microbiol Immunol 2008 ; 52 : 621-4.
PubMed
12) 川名誠司, 上野孝, 下田貴子. ざ瘡に対するRoxithromycin (ルリッド(R)) の長期継続投与の効果-Minocycline Hydrochlorideとの比較. 西日皮膚 2007 ; 69 : 424-7.
 
13) Nishijima S, Kurokawa I, Katoh N, et al. The bacteriology of acne vulgaris and antimicrobial susceptibility of Propionibacterium acnes and Staphylococcus epidermidis isolated from acne lesions. J Dermatol 2000 ; 27 : 318-23.
PubMed
14) 坪井良治, 小池美佳, 瀧本玲子, ほか. 膿疱性ざ瘡に対するciprofloxacin錠の臨床的検討-Minocycline錠との比較. 化学療法の領域 1999 ; 15 : 95-102.
 
15) 西嶋攝子, 黒川一郎, 河端繁勝. 尋常性ざ瘡病巣より分離したPropionibacterium acnesの薬剤感受性について. 皮膚科紀要 1996 ; 91 : 497-501.
 
16) 上野一恵, 加藤直樹, 渡辺邦友, ほか, 尋常性ざ瘡に対するOPC-7251クリーム剤の細菌学的効果. Chemotherapy 1990 ; 38 : 1048-59.
 
17) 黒川一郎, 西嶋攝子, 朝田康夫. Propionibacterium acnesの抗生物質感受性-関西医大皮膚科における過去15年間の変遷. 日皮会誌 1986 ; 96 : 1655-60.
 
18) 浦田裕次, 森俊二, 渡辺邦友, ほか. 健常人皮膚および皮膚感染巣におけるPropionibacterium属, Staphylococcus属, Streptococcus属およびEnterococcus属の分布に関する研究 (II) -皮膚感染巣におけるPropionibacterium属, Staphylococcus属, Streptococcus属およびEnterococcus属の分布. 岐阜大医紀 1985 ; 33 : 500-23.
 
19) 遠藤英樹, 和田珠恵, 成田智彦, ほか. 炎症性皮疹をともなう尋常性ざ瘡に対するfaropenem (FRPM) の臨床研究-尋常性ざ瘡患者由来Propionibacterium acnesおよびStaphylococcus epidermidisに対する各種抗菌薬の抗菌活性. 化学療法の領域 2009 ; 25 : 95-102.
 
20) 松崎薫, 大美賀薫, 長谷川美幸, ほか. 皮膚科感染症由来Staphylococcus属およびPropionibacterium属に対するNadifloxacinの抗菌活性. Jpn J Antibiotics 2006 ; 59 : 316-20.
 
21) CLDM-T研究会. リン酸クリンダマイシン外用ゲル剤 (CLDM-T) の尋常性ざ瘡に対する第III相試験-ナジフロキサシンクリームを対照とした無作為割付け群間比較試験. 臨床医薬 1999 ; 15 : 603-28.
 
22) RXMざ瘡研究会. Roxithromycinの炎症性皮疹を伴う尋常性ざ瘡 (膿疱性ざ瘡) における臨床的検討. 西日皮膚 1997 ; 59 : 444-50.
 
23) 橋本明彦, 坪井廣美, 平松正浩, ほか. ざ瘡に対するRoxithromycin (ルリッド(R)) の有用性-Minocyclineとの比較検討. 西日皮膚 1996 ; 58 : 135-7.
 
24) 中村健一, 川名誠司, 原田晴美, ほか. Roxithromycin (ルリッド(R)) の有用性. 西日皮膚 1993 ; 55 : 1136-40.
 
25) 植松茂生. 毛包性膿皮症とざ瘡に対するrokitamycin錠の臨床効果-Minocycline錠との比較. Chemotherapy 1992 ; 40 : 504-8.
 
26) Ross JI, Snelling AM, Eady EA, et al. Phenotypic and genotypic characterization of antibiotic-resistant Propionibacterium acnes isolated from acne patients attending dermatology clinics in Europe, the U.S.A., Japan and Australia. Br J Dermatol 2001 ; 144 : 339-46.
 
27) Nishijima S, Akamatsu H, Akamatsu M, et al. The antibiotic susceptibility of Propionibacterium acnes and Staphylococcus epidermidis isolated from acne. J Dermatol 1994 ; 21 : 166-71.
PubMed
28) Oprica C, Emtestam L, Hagstromer L, et al. Clinical and microbiological comparisons of isotretinoin vs. tetracycline in acne vulgaris. Acta Derm Venereol 2007 ; 87 : 246-54.
PubMed
29) 星野都. アクアチム発売15年の歩み. アレルギーの臨床 2009 ; 29 : 434-9.
 
30) 駒形安子, 小宮山寛機. Propionibacterium acnesに対するClindamycinの抗菌性に関する基礎的検討. Jpn J Antibiotics 1998 ; 51 : 130-6.
 
31) Eady EA, Bojar RA, Jones CE, et al. The effects of acne treatment with a combination of benzoyl peroxide and erythromycin on skin carriage of erythromycin-resistant propionibacteria. Br J Dermatol 1996 ; 134 : 107-13.
PubMed
32) Coates P, Vyakrnam S, Ravenscroft JC, et al. Efficacy of oral isotretinoin in the control of skin and nasal colonization by antibiotic-resistant propionibacteria in patients with acne. Br J Dermatol 2005 ; 153 : 1126-36.
PubMed
33) Dreno B, Foulc P, Reynaud A, et al. Effect of zinc gluconate on Propionibacterium acnes resistance to erythromycin in patients with inflammatory acne : in vitro and in vivo study. Eur J Dermatol 2005 ; 15 : 152-5.
PubMed
34) Kinney MA, Yentzer BA, Fleischer AB Jr, et al. Trends in the treatment of acne vulgaris : are measures being taken to avoid antimicrobial resistance? J Drugs Dermatol 2010 ; 9 : 519-24.
PubMed
35) Burkhart CN, Burkhart CG. Antibiotic-resistant Propionibacteria acnes may not be the major issue clinically or microbiologically in acne. Br J Dermatol 2003 ; 148 : 365-6.
 
36) 西嶋攝子. ざ瘡の新しい治療. 皮膚の科学 2003 ; 2 : 155-9.
 
P.280 掲載の参考文献
1) Thiboutot D, Gollnick H, Bettoli V, et al. New insight into the management of acne : an update from the Global Alliance to Improve Outcomes in Acne group. J Am Acad Dermatol 2009 ; 60 : S1-50.
 
1) 林伸和, 赤松浩彦, 岩月啓氏, ほか. 尋常性ざ瘡治療ガイドライン. 日皮会誌 2008 ; 118 : 1893-923.
 
2) Gollnick H, Cunliff W, Berson D, et al. Management of acne : a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol 2003 ; 49 : S1-37.
 
3) Thiboutot DM, Weiss J, Bucko A, et al. Adapalene-benzoyl peroxide, a fixed-dose combination for the treatment of acne vulgaris : results of a multicenter, randomized double-blind, controlled study. J Am Acad Dermatol 2007 ; 57 : 791-9.
PubMed

VII 最新研究からのインサイト

P.288 掲載の参考文献
1) Kobayashi M, Yoshiki R, Sakabe J, et al. Expression of toll-like receptor 2, NOD2 and dectin-1 and stimulatory effects of their ligands and histamine in normal human keratinocytes. Br J Dermatol 2009 ; 160 : 297-304.
PubMed
2) Kim J, Ochoa MT, Krutzik SR, et al. Activation of toll-like receptor 2 in acne triggers inflammatory cytokine responses. J Immunol 2002 ; 169 : 1535-41.
PubMed
3) Jugeau S, Tenaud I, Knol AC, et al. Induction of toll-like receptors by Propionibacterium acnes. Br J Dermatol 2005 ; 153 : 1105-13.
PubMed
4) Tokura Y, Edelson RL, Gasparro FP. Retinoid augmentation of bioactive interleukin-1 production by murine keratinocytes. Br J Dermatol 1992 ; 126 : 485-95.
PubMed
5) Liu PT, Krutzik SR, Kim J, et al. Cutting edge : all-trans retinoic acid down-regulates TLR2 expression and function. J Immunol 2005 ; 174 : 2467-70.
PubMed
6) Tenaud I, Khammari A, Dreno B. In vitro modulation of TLR-2, CD1d and IL-10 by adapalene on normal human skin and acne inflammatory lesions. Exp Dermatol 2007 ; 16 : 500-6.
PubMed
P.292 掲載の参考文献
1) Rosenfield RL. Relationship of sebaceous cell stage to growth in culture. J Invest Dermatol 1989 ; 92 : 751-4.
PubMed
2) Ito A, Sakiguchi T, Akamatsu H, et al. Establishment of a tissue culture system for hamster sebaceous gland cells. Dermatology 1998 ; 197 : 238-44.
PubMed
3) Sato T, Imai N, Akimoto N, et al. Epidermal growth factor and 1α, 25-dihydroxyvitamin D3 suppress lipogenesis in hamster sebaceous gland cells in vitro. J Invest Dermatol 2001 ; 117 : 965-70.
 
4) Akazawa Y, Sayo T, Sugiyama Y, et al. Adiponectin resides in mouse skin and upregulates hyaluronan synthesis in dermal fibroblasts. Connective Tissue Res 2011 ; 52 : 322-8.
 
5) Xia LQ, Zouboulis C, Detmar M, et al. Isolation of human sebaceous glands and cultivation of sebaceous gland-derived cells as an in vitro model. J Invest Dermatol 1989 ; 93 : 315-21.
 
6) Zouboulis CC, Seltmann H, Neitzel H, et al. Establishment and characterization of an immortalized human sebaceous gland cell line (SZ95). J Invest Dermatol 1999 ; 113 : 1011-20.
PubMed
7) Thiboutot D, Jabara S, McAllister JM, et al. Human skin is a steroidogenic tissue : steroidogenic enzymes and cofactors are expressed in epidermis, normal sebocytes, and an immortalized sebocyte cell line (SEB-1). J Invest Dermatol 2003 ; 120 : 905-14.
 
8) Lo Celso C, Berta MA, Braun KM, et al. Characterization of bipotential epidermal progenitors derived from human sebaceous gland : contrasting roles of c-Myc and β-catenin. Stem Cells 2008 ; 26 : 1241-52.
 
9) Iwata C, Akimoto N, Sato T, et al. Augmentation of lipogenesis by 15 -deoxy-Δ12,14-prostaglandin J2 in hamster sebaceous glands : identification of cytochrome P-450-mediated 15 -deoxy-Δ12,14-prostaglandin J2 production. J Invest Dermatol 2005 ; 125 : 865-72.
 
10) Zouboulis CC. Zileuton, a new efficient and safe systemic anti-acne drug. Dermatoendocrinol 2009 ; 1 : 188-92.
PubMed
11) Bohm M. Neuroendocrine regulators : novel trends in sebaceous gland research with future perspectives for the treatment of acne and related disorders. Dermatoendocrinol 2009 ; 1 : 136-40.
PubMed
12) Bohm M, Schiller M, Stander S, et al. Evidence for expression of melanocortin-1 receptor in human sebocytes in vitro and in situ. J Invest Dermatol 2002 ; 118 : 533-9.
 
13) Nagai A, Sato T, Akimoto N, et al. Isolation and identification of histone H3 protein enriched in microvesicles secreted from cultured sebocytes. Endocrinology 2005 ; 146 : 2593-601.
PubMed
14) Sato T, Takahashi A, Kojima M, et al. A citrus polymethoxy flavonoid, nobiletin inhibits sebum production and sebocyte proliferation, and augments sebum excretion in hamsters. J Invest Dermatol 2007 ; 127 : 2740-8.
PubMed
15) Sato T, Ito A. Beneficial actions of citrus polymethoxy flavonoids in treating acne. Clin Dermatol, Retinoids & Other Treatments 2008 ; 24 : 22-6.
 
16) Kurihara H, Sato T, Akimoto N, et al. Identification and characterization of ABCB1-mediated and non-apoptotic sebum secretion in differentiated hamster sebocytes. Biochim Biophys Acta 2011 ; 1811 : 1090-6.
PubMed
17) Toth BI, Geczy T, Griger Z, et al. Transient receptor potential vanilloid-1 signaling as a regulator of human sebocyte biology. J Invest Dermatol 2009 ; 129 : 329-39.
PubMed
P.298 掲載の参考文献
1) Crawford GH, Pelle MT, James WD. Rosacea : I. Etiology, pathogenesis, and subtype classification. J Am Acad Dermatol 2004 ; 51 : 327-41 ; quiz 342-4.
 
2) Bonnar E, Eustace P, Powell FC. The Demodex mite population in rosacea. J Am Acad Dermatol 1993 ; 28 : 443-8.
PubMed
3) Forton F, Seys B. Density of Demodex folliculorum in rosacea : a case-control study using standardized skin-surface biopsy. Br J Dermatol 1993 ; 128 : 650-9.
PubMed
4) Erbagci Z, Ozgoztasi O. The significance of Demodex folliculorum density in rosacea. Int J Dermatol 1998 ; 37 : 421-5.
PubMed
5) Rebora A, Drago F, Picciotto A. Helicobacter pylori in patients with rosacea. Am J Gastroenterol 1994 ; 89 : 1603-4.
PubMed
6) Diaz C, O'Callaghan CJ, Khan A, et al. Rosacea : a cutaneous marker of Helicobacter pylori infection? Results of a pilot study. Acta Derm Venereol 2003 ; 83 : 282-6.
 
7) Argenziano G, Donnarumma G, Iovene MR, et al. Incidence of anti-Helicobacter pylori and anti-CagA antibodies in rosacea patients. Int J Dermatol 2003 ; 42 : 601-4.
PubMed
8) Szlachcic A. The link between Helicobacter pylori infection and rosacea. J Eur Acad Dermatol Venereol 2002 ; 16 : 328-33.
PubMed
9) Jones MP, Knable AL Jr, White MJ, et al. Helicobacter pylori in rosacea : lack of an association. Arch Dermatol 1998 ; 134 : 511.
PubMed
10) Dorschner RA, Pestonjamasp VK, Tamakuwala S, et al. Cutaneous injury induces the release of cathelicidin anti-microbial peptides active against group A Streptococcus. J Invest Dermatol 2001 ; 117 : 91-7.
PubMed
11) Yamasaki K, Di Nardo A, Bardan A, et al. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat Med 2007 ; 13 : 975-80.
PubMed
12) Yamasaki K, Gallo RL. Antimicrobial peptides in human skin disease. Eur J Dermatol 2008 ; 18 : 11-21.
PubMed
13) Murakami M, Lopez-Garcia B, Braff M, et al. Postsecretory processing generates multiple cathelicidins for enhanced topical antimicrobial defense. J Immunol 2004 ; 172 : 3070-7.
PubMed
14) Braff MH, Hawkins MA, Di Nardo A, et al. Structure-function relationships among human cathelicidin peptides : dissociation of antimicrobial properties from host immunostimulatory activities. J Immunol 2005 ; 174 : 4271-8.
PubMed
15) Yamasaki K, Schauber J, Coda A, et al. Kallikrein-mediated proteolysis regulates the antimicrobial effects of cathelicidins in skin. FASEB J 2006 ; 20 : 2068-80.
PubMed
16) Schauber J, Dorschner RA, Coda AB, et al. Injury enhances TLR2 function and antimicrobial peptide expression through a vitamin D-dependent mechanism. J Clin Invest 2007 ; 117 : 803-11.
PubMed
17) Liu PT, Stenger S, Li H, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006 ; 311 : 1770-3.
PubMed
18) Yamasaki K, Kanada K, Macleod DT, et al. TLR2 expression is increased in rosacea and stimulates enhanced serine protease production by keratinocytes. J Invest Dermatol 2010 ; 131 : 688-97.
PubMed
19) Sapadin AN, Fleischmajer R. Tetracyclines : nonantibiotic properties and their clinical implications. J Am Acad Dermatol 2006 ; 54 : 258-65.
PubMed
20) Gallo R, Yamasaki K. Azelaic acid gel alters kallikrein 5 and cathelicidin expression in epidermal keratinocytes, critical elements in the pathogenesis of rosacea. J Am Acad Dermatol 2010 ; 62 (Suppl 1) : AB1.
 
P.303 掲載の参考文献
1) ミュア・グレイJA, 著. 斉尾武郎, 監訳. 患者は何でも知っている-EBM時代の医師と患者. 東京 : 中山書店 ; 2004.
 
1) 林伸和, 赤松浩彦, 岩月啓氏, ほか. 尋常性ざ瘡治療ガイドライン. 日皮会誌 2008 ; 118 : 1893-923.
 
2) 安保寛明, 武藤教志. コンコーダンス-患者の気持ちに寄り添うためのスキル 21. 東京 : 医学書院 ; 2010.
 
2) 幸野健, 谷口彰治. 皮膚疾患におけるEBMとガイドライン-世界医療の潮流と皮膚科学. 玉置邦彦, ほか編. 最新皮膚科学大系 2006-2007. 東京 : 中山書店 ; 2006. pp2-13.
 
3) Cushing A, Metcalfe R. Optimizing medicines management : from compliance to concordance. Ther Clin Risk Manag 2007 ; 3 : 1047-58.
PubMed
4) 福島雅典, 監訳. メルクマニュアル医学百科家庭版. 2004 (オンライン版). (http://merckmanual.jp/mmhe2j/index.html)
 
5) アポネットR研究会. コンコーダンスとは. 2004. (http://www.watarase.ne.jp/aponet/keywords/concordance/page1.html)
 
6) Matsuyama JR, Mason BJ, Jue SG. Pharmacists' interventions using an electronic medication-event monitoring device's adherence data versus pill counts. Ann Pharmacother 1993 ; 27 : 851-5.
PubMed
7) Balkrishnan R, Carroll CL, Camacho FT, et al. Electronic monitoring of medication adherence in skin disease : results of a pilot study. J Am Acad Dermatol 2003 ; 49 : 651-4.
PubMed
8) Carroll CL, Feldman SR, Camacho FT, et al. Adherence to topical therapy decreases during the course of an 8-week psoriasis clinical trial : commonly used methods of measuring adherence to topical therapy overestimate actual use. J Am Acad Dermatol 2004 ; 51 : 212-6.
PubMed
9) Krejci-Manwaring J, Tusa MG, Carroll C, et al. Stealth monitoring of adherence to topical medication : adherence is very poor in children with atopic dermatitis. J Am Acad Dermatol 2007 ; 56 : 211-6.
PubMed
10) Kellett N, West F, Finlay AY. Conjoint analysis : a novel rigorous tool for determining patient preference for topical antibiotic treatment for acne. A randomized controlled trial. Br J Dermatol 2006 ; 154 : 524-32.
 
11) Feldman SR. ざ瘡治療を含めた皮膚疾患の局所療法におけるアドヒアランスの向上. The 70th Annual Meeting of the Society for Investigative Dermatology講演録. 東京 : ガルデルマ ; 2010.
 
12) Cook-Bolden F. Subject preferences for acne treatments containing adapalene gel 0.1% : results of MORE trial. Cutis 2006 ; 78 (suppl 1) : 26-33.
 
13) 五十嵐敦之, 丸口幸也, 菊地克子. ニキビ治療におけるアドヒアランスの重要性. Dermatology Now 2009 ; 3 : 3-7.
 
14) 丸口幸也. アドヒアランスを上げるコツ. MB Derma 2010 ; 170 : 107-11.
 
15) 日本高血圧学会治療ガイドライン作成委員会. 高血圧治療ガイドライン 2009. (http://minds.jcqhc.or.jp/stc/0019/1/0019_G0000180_GL.html)
 
P.307 掲載の参考文献
1) Gold LS, Tan J, Cruz-Santana A, et al ; Adapalene-BPO Study Group. A North American study of adapalene-benzoyl peroxide combination gel in the treatment of acne. Cutis 2009 ; 84 : 110-6.
 
2) Draelos ZD, Carter E, Maloney JM, et al ; United States/Canada Dapsone Gel Study Group. Two randomized studies demonstrate the efficacy and safety of dapsone gel, 5% for the treatment of acne vulgaris. J Am Acad Dermatol 2007 ; 56 : 439.e1-10.
 
3) Lucky AW, Maloney JM, Roberts J, et al ; Dapsone Gel Long-Term Safety Study Group. Dapsone gel 5% for the treatment of acne vulgaris : safety and efficacy of long-term (1 year) treatment. J Drugs Dermatol 2007 ; 6 : 981-7.
 
4) Raimer S, Maloney JM, Bourcier M, et al ; United States/Canada Dapsone Gel Study Group. Efficacy and safety of dapsone gel 5% for the treatment of acne vulgaris in adolescents. Cutis 2008 ; 81 : 171-8.
 
5) Fleischer AB Jr, Shalita A, Eichenfield LF, et al ; Dapsone Gel in Combination Treatment Study Group. Dapsone gel 5% in combination with adapalene gel 0.1%, benzoyl peroxide gel 4% or moisturizer for the treatment of acne vulgaris : a 12-week, randomized, double-blind study. J Drugs Dermatol 2010 ; 9 : 33-40.
PubMed
6) Katsambas A, Graupe K, Stratigos J. Clinical studies of 20% azelaic acid cream in the treatment of acne vulgaris : comparison with vehicle and topical tretinoin. Acta Derm Venereol Suppl (Stockh) 1989 ; 143 : 35-9.
PubMed
7) 尾花俊作, 麻生五月, 三谷てるみ, ほか. 20% Azelaic acidクリームによるざ瘡の治験. 皮膚 1987 ; 29 : 120-7.
 
8) 川島眞, 林伸和, 小柳衣吏子. 20%アゼライン酸クリーム (R410) の本邦尋常性ざ瘡患者における有効性および安全性の検討. 日本美容皮膚科学会雑誌 2011 ; 21 : 32-41.
 
9) Antonio JR, Pegas JR, Cestari TF, et al. Azithromycin pulses in the treatment of inflammatory and pustular acne : efficacy, tolerability and safety. J Dermatolog Treat 2008 ; 19 : 210-5.
 
10) Rafiei R, Yaghoobi R. Azithromycin versus tetracycline in the treatment of acne vulgaris. J Dermatolog Treat 2006 ; 17 : 217-21.
PubMed
11) Kus S, Yucelten D, Aytug A. Comparison of efficacy of azithromycin vs. doxycycline in the treatment of acne vulgaris. Clin Exp Dermatol 2005 ; 30 : 215-20.
PubMed
12) Parsad D, Pandhi R, Nagpal R, et al. Azithromycin monthly pulse vs daily doxycycline in the treatment of acne vulgaris. J Dermatol 2001 ; 28 : 1-4.
PubMed
13) Thiboutot D, Gollnick H, Bettoli V, et al. New insights into the management of acne : an update from the global alliance to improve outcomes in acne group. J Am Acad Dermatol 2009 ; 60 : S1-50.
 

書評

最近チェックした商品履歴

Loading...